polymer dyes
Patent Information
- Application Number
- JP2023531606
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-25
- Filing Date
- 2021-11-22
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Conventional hybridization assays using solid surfaces for nucleic acid immobilization face challenges such as reduced mobility of probes, increased hybridization time, interference with signal detection, and inability for in vivo detection, leading to high signal-to-noise ratios.
Development of polymeric chromophore-covalently attached polynucleotides, including compounds with structures (I), (II), and (III), which allow for improved probe brightness and lower signal-to-noise ratios through the use of polynucleotide linkers and chromophores, enabling in vivo detection and simultaneous detection of nucleic acids.
The proposed compounds enhance probe brightness and reduce signal-to-noise ratios, facilitating efficient and accurate nucleic acid detection without the limitations of solid surfaces, thereby improving the speed and accuracy of hybridization assays.
Smart Images

Figure 2022115388000001 
Figure 2022115388000002 
Figure 2022115388000003
Abstract
Description
[Technical Field]
[0001] Statement regarding sequence listings The sequence listing relating to this application is provided in text format instead of on paper and is incorporated herein by reference. The name of the text file containing the sequence listing is 870268_430WO_SEQUENCE_LISTING.txt. The text file is 4.1 KB in size, was created on November 19, 2021, and submitted electronically via EFS-Web.
[0002] This disclosure generally covers compounds comprising a polymer chromophore covalently bonded to at least one polynucleotide (e.g., compounds comprising a polymer fluorophore moiety bonded to a nucleotide probe), as well as compositions and kits comprising the same, and methods for preparing and using them in various analytical methods. [Background technology]
[0003] Probes are used to detect specific target sequences or other analytes in various diagnostic and analytical situations. For example, conventional, heterogeneous hybridization assays typically involve the following steps: immobilization of the target nucleic acid (e.g., onto a paper, bead, or plastic surface); addition of a labeled probe complementary to the target sequence; hybridization; removal of unhybridized probes; and detection of probes remaining bound to the immobilized target. However, using a solid surface to immobilize the target nucleic acid increases the hybridization time by limiting the mobility of the probe to the target or its access to the target. Furthermore, solid surfaces may interfere with the signal from the probe or introduce noise into the signal. The conditions under which the probe-target hybrid is isolated also hinder in vivo detection and simultaneous detection of nucleic acids during synthesis (real-time detection). Therefore, there is a need in the art for an improved probe that has increased brightness and generates a lower signal-to-noise ratio. The present disclosure meets this need and provides further related advantages. SUMMARY OF THE INVENTION
[0004] In one aspect, compounds having the following structure (II) or stereoisomers, salts or tautomers thereof are described herein.
Chemical formula
[0005] In another embodiment, the present disclosure provides a compound having the following structure (III) or a stereoisomer, salt, or tautomer thereof. [ka] (III) (In the formula, M is the same or different chromophore in each occurrence, independently. L1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L 3 , L 5 , L 6 and L 7 Each instance is independently any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 4 Each occurrence is independently alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 10 It is a linker containing polynucleotides, R 1 and R 2 R 1 and R 2 If at least one of the parts contains a polynucleotide, then each can be independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , or a portion containing polynucleotides, R 3 In each occurrence, it is independently H, alkyl, or alkoxy. R 4 In each occurrence, OH, SH, and O appear independently. - S - , OR d or SR d And, R 5 In each occurrence, independently, it is either oxo, thioxo, or absent. R a is either O or S, R b OH, SH, O - S - , OR d or SR d And, R c OH, SH, O - S - , OR d ,OL',SR d Alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 2, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0006] In further embodiments, compositions comprising a compound of structure (II) and a capture probe are described herein. Compositions comprising compounds of structure (II) and compounds of structure (III) are also described herein.
[0007] In further embodiments, compositions comprising a compound of structure (III) and a compound having the following structure (I) or its stereoisomers, salts, or tautomers are described herein. [ka] (I) (In the formula, M is the same or different chromophore in each occurrence, independently. L 1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L3 and L 5 and L 6 and L 7 is, independently at each occurrence, any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene or heteroalkynylene linker, L 4 is, independently at each occurrence, an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene or heteroalkynylene linker, R 1 and R 2 is R 1 and R 2 If at least one of R a )(R b )R c and R R 3 is, independently at each occurrence, H, alkyl or alkoxy, R 4 is, independently at each occurrence, OH, SH, O - S - OR d or SR d is, R 5 is, independently at each occurrence, oxo, thioxo or absent, R a is O or S, R b is OH, SH, O - S - OR d or SR d is, R c is OH, SH, O - S - OR d OL’, SR dAlkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 1, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0008] A composition comprising (1) a capture probe comprising a second segment comprising (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of alternating second polynucleotides and a first polymer, each of the first polymers comprising a first chromophore and each of the second polynucleotides comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a third polynucleotide covalently bonded to at least one second polymer comprising a second chromophore, wherein the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence, is also described herein.
[0009] In yet another embodiment, compositions are described herein that include (1) a capture probe comprising a second segment comprising (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides each comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a plurality of detectable probes comprising a third polynucleotide having a first end and a second end, the first end being covalently bonded to a first polymer comprising an acceptor chromophore, and the second end being covalently bonded to a second polymer comprising a donor chromophore, wherein the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence.
[0010] Furthermore, kits containing compounds of the compositions described herein are also described herein. In further embodiments, the present disclosure provides a method for identifying the presence of a target analyte, comprising the steps of: generating a mixture by contacting a sample with a composition described herein under assay conditions; and imaging the mixture under detection conditions.
[0011] The patent or application file includes at least one drawing made in color. Copies of the publication of the patent or application accompanied by the color drawing will be provided by the Patent Office upon request and payment of the necessary fees. In the diagram, the same reference number identifies similar elements. The size and relative position of the elements in the diagram are not necessarily to exact scale, and some of these elements are enlarged and positioned to improve the readability of the diagram. Furthermore, the specific shapes of the elements depicted are not intended to convey any information about the actual shape of the particular element, but are simply chosen to facilitate recognition of the diagram. [Brief explanation of the drawing]
[0012] [Figure 1] This figure shows a schematic diagram of an embodiment of the probe composite. [Figure 2A] This figure shows a schematic diagram of another embodiment of the probe complex. [Figure 2B] This figure shows a diagram of a further embodiment of the probe complex. [Figure 2C] This figure shows a diagram of a further embodiment of the probe complex. [Figure 3A] This figure shows a diagram of a further embodiment of the probe complex. [Figure 3B] This figure shows a diagram of a further embodiment of the probe complex. [Figure 4] This figure shows the results of the inspection described in Example 3. [Figure 5] This figure shows the results of the inspection described in Example 5. [Figure 6] This figure shows the results of the inspection described in Example 6. [Figure 7] This figure illustrates an embodiment of concatemerization of the probe described in Example 7. [Figure 8A] This figure shows the results of the inspection described in Example 8. [Figure 8B] This figure shows the results of the inspection described in Example 8. [Modes for carrying out the invention]
[0013] In the following description, certain specific details are provided to give a full understanding of the various embodiments of the invention. However, those skilled in the art will understand that the invention can be carried out without these details. Unless required by context, throughout this specification and the claims, the word “comprise,” and its variations, such as “comprises” and “comprising,” should be interpreted as having an open and inclusive meaning, i.e., “including, but not limited to.” Throughout this specification, any reference to “one embodiment” or “an embodiment” means that the specific features, structures, or characteristics described in relation to that embodiment are included in at least one embodiment of the present invention. Therefore, the appearance of the phrase “in one embodiment” or “in one embodiment” in various places throughout this specification does not necessarily refer to all of the same embodiments. Furthermore, specific features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0014] "Amino" refers to the -NH2 group. "Carboxylate" refers to the -CO2H group. "Cyano" refers to the -CN group. "Formyl" refers to the -C(=O)H group. "Hydroxy" or "hydroxyl" refers to the -OH group. "Imino" refers to the NH group. "Nitro" refers to the -NO2 group. "Oxo" refers to an =O substituent. "Sulfhydryl" refers to the -SH group. "Thioxo" refers to the S group. "Alkyl" refers to a linear or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, without unsaturation, having 1 to 12 carbon atoms (C1-C12 alkyl), 1 to 8 carbon atoms (C1-C8 alkyl), or 1 to 6 carbon atoms (C1-C6 alkyl), and bonded to the rest of the molecule by a single bond, such as methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, etc. Unless otherwise specifically described herein, alkyl groups may be substituted.
[0015] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain consisting only of carbon and hydrogen, containing no unsaturated atoms, and having 1 to 12 carbon atoms, with the rest of the molecule linked to a radical group. Examples include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, and n-butynylene. The alkylene chain is bonded to the rest of the molecule and to the radical group via single bonds. The bonding sites of the alkylene chain to the rest of the molecule and the radical group may be via one carbon or any two carbons in the chain. Unless specifically described herein, alkylenes may be substituted. "Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain consisting only of carbon and hydrogen, containing at least one carbon-carbon double bond, and having 2 to 12 carbon atoms, linking the rest of the molecule to a radical group, such as etenylene, propenylene, and n-butenylene. The alkenylene chain is bonded to the rest of the molecule via single bonds and to the radical group via double or single bonds. The bonding sites of the alkenylene chain to the rest of the molecule and the radical group may be via one carbon or any two carbons in the chain. Unless specifically described herein, alkenylenes may be substituted.
[0016] "Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain consisting only of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having 2 to 12 carbon atoms, linking the rest of the molecule to a radical group, such as etenylene, propenylene, and n-butenylene. The alkynylene chain is bonded to the rest of the molecule via single bonds and to the radical group via double or single bonds. The bonding sites of the alkynylene chain to the rest of the molecule and the radical group may be via one carbon or any two carbons in the chain. Unless specifically described herein, alkynylene may be substituted. "Alkyl ether" refers to any alkyl group as defined above, in which at least one carbon-carbon bond is replaced by a carbon-oxygen bond. The carbon-oxygen bond may be terminal (similar to an alkoxy group), or the carbon-oxygen bond may be internal (i.e., COC). Alkyl ethers contain at least one carbon-oxygen bond, but may contain more than one. For example, polyethylene glycol (PEG) falls within the meaning of alkyl ether. Unless specifically described herein, alkyl ether groups may be substituted. For example, in some embodiments, the alkyl ether is substituted with an alcohol or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are as defined for the compound in structure (I)).
[0017] "Alkoxy" refers to a group of the formula -ORa (wherein Ra is an alkyl group as defined above, containing 1 to 12 carbon atoms). Unless otherwise specifically described herein, alkoxy groups may be substituted. "Alkoxyalkyl ether" refers to a group of formula -ORaRb (wherein Ra is an alkylene group containing 1 to 12 carbon atoms as defined above, and Rb is an alkyl ether group as defined herein). Unless otherwise specifically described herein, alkoxyalkyl ethers may be substituted, for example, with an alcohol or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are as defined for the compound of structure (I)).
[0018] "Heteroalkyl" refers to the alkyl group as defined above, which contains at least one heteroatom (e.g., N, O, P, or S) within or at the terminus of the alkyl group. In some embodiments, the heteroatom is within the alkyl group (i.e., the heteroalkyl group contains at least one carbon-[heteroatom]x-carbon bond, (x is 1, 2, or 3)). In other embodiments, the heteroatom is at the terminus of the alkyl group and thus serves to bond the alkyl group to the rest of the molecule (e.g., M1-HA (wherein M1 is a molecule, H is a heteroatom, and A is an alkyl group)). Unless specifically described herein, heteroalkyl groups may be substituted. Exemplary heteroalkyl groups include ethylene oxide (e.g., polyethylene oxide), which may contain a phosphorus-oxygen bond, e.g., a phosphodiester bond. "Heteroalkoxy" refers to a group of formula -ORa (wherein Ra is a heteroalkyl group defined above, containing 1 to 12 carbon atoms). Unless otherwise specifically described herein, heteroalkoxy groups may be substituted.
[0019] "Heteroalkylene" refers to an alkyl group as defined above, which contains at least one heteroatom (e.g., N, O, P, or S) within or at the end of an alkylene chain. In some embodiments, the heteroatom is within the alkylene chain (i.e., the heteroalkylene contains at least one carbon-[heteroatom]-carbon bond, where x is 1, 2, or 3). In other embodiments, the heteroatom is at the end of the alkylene and thus serves to bond the alkylene to the rest of the molecule (e.g., M1-HA-M2, where M1 and M2 are part of the molecule, H is the heteroatom, and A is the alkylene group). Unless specifically described herein, heteroalkylene groups may be substituted. Exemplary heteroalkylene groups include ethylene oxide (e.g., polyethylene oxide), as well as the linking groups "C", "HEG", "TEG", "PEG 1K" and their variations, as exemplified below. [ka]
[0020] The above-mentioned C linker, HEG linker, and / or PEG 1K linker polymers are included in various embodiments of the heteroalkylene linker. In some embodiments of the PEG 1K linker, n is 25. The polymer may include, for example, the following structure: [ka] (In the formula, x is an integer greater than or equal to 0, for example, x is in the range of 0 to 100 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10)) A "heteroalkenylene" is a heteroalkylene as defined above, containing at least one carbon-carbon double bond. Unless otherwise specifically described herein, the heteroalkenylene group may be substituted.
[0021] A "heteroalkylene" is a heteroalkylene containing at least one carbon-carbon triple bond. Unless otherwise specifically described herein, the heteroalkylene group may be substituted. In relation to "heteroatom linkers," "heteroatom" refers to a linker group consisting of one or more heteroatoms. Exemplary heteroatom linkers include monatoms selected from the group consisting of O, N, P, and S, as well as multiple heteroatoms, such as linkers having the formulas -P(O-)(=O)O- or OP(O-)(=O)O-, and polymers and combinations thereof. "Phosphate" refers to the -OP(=O)(Ra)Rb group (wherein Ra is OH, O-, or ORc, Rb is OH, O-, ORc, a thiophosphate group, or a further phosphate group, and Rc is a counterion (e.g., Na+)).
[0022] "Phosphoalkyl" refers to the -OP(=O)(Ra)Rb group (wherein Ra is OH, O-, or ORc, Rb is -O alkyl, and Rc is a counterion (e.g., Na+)). Unless otherwise specifically described herein, phosphoalkyl groups may be substituted. For example, in certain embodiments, the -O alkyl portion of a phosphoalkyl group may be substituted with one or more of the following: hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are each as defined for the compound of structure (I)). "Phosphoalkyl ether" refers to the -OP(=O)(Ra)Rb group (wherein Ra is OH, O-, or ORc, Rb is a -O alkyl ether, and Rc is a counterion (e.g., Na+)). Unless otherwise specifically described herein, the phosphoalkyl ether group may be substituted. For example, in certain embodiments, the -O alkyl ether portion of the phosphoalkyl ether group may be substituted with one or more of the following: hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are each as defined for the compound of structure (I)).
[0023] "Thiophage" refers to the -OP(=Ra)(Rb)Rc group (wherein Ra is O or S, Rb is OH, O-, S-, ORd or SRd, Rc is OH, SH, O-, S-, ORd, SRd, phosphate group or further thiophosphate group, and Rd is a counterion (e.g., Na+), provided that i) Ra is S, ii) Rb is S- or SRd, iii) Rc is SH, S- or SRd, or iv) a combination of i), ii) and / or iii)). "Thiophosphoalkyl" refers to the -OP(=Ra)(Rb)Rc group (wherein Ra is O or S, Rb is OH, O-, S-, ORd or SRd, Rc is -O alkyl, and Rd is a counterion (e.g., Na+), provided that i) Ra is S, ii) Rb is S- or SRd, or iii) Ra is S and Rb is S- or SRd). Unless otherwise specifically described herein, thiophosphoalkyl groups may be substituted. For example, in certain embodiments, the -O alkyl portion of a thiophosphoalkyl group may be substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are each as defined for the compound of structure (I)).
[0024] "Thiophosphoalkyl ether" refers to the -OP(=Ra)(Rb)Rc group (wherein Ra is O or S, Rb is OH, O-, S-, ORd or SRd, Rc is an -O alkyl ether, and Rd is a counterion (e.g., Na+), provided that i) Ra is S, ii) Rb is S- or SRd, or iii) Ra is S and Rb is S- or SRd). Unless otherwise specifically described herein, the thiophosphoalkyl ether group may be substituted. For example, in certain embodiments, the -O alkyl ether portion of the thiophosphoalkyl group may be substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are each as defined for the compound of structure (I)).
[0025] "Carbocyclic" refers to a stable 3-18 member aromatic or non-aromatic ring containing 3-18 carbon atoms. Unless otherwise specifically described herein, carbocyclic rings may be monocyclic, dicyclic, tricyclic, or tetracyclic ring systems, which may include condensed or bridging ring systems and may be partially or completely saturated. Non-aromatic carbocyclyl radicals include cycloalkyl groups, while aromatic carbocyclyl radicals include aryl groups. Unless otherwise specifically described herein, carbocyclic groups may be substituted. "Cycloalkyl" refers to a stable, non-aromatic monocyclic or polycyclic carbocyclic ring, which may include condensed or cross-linked ring systems, having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, being saturated or unsaturated, and bonded to the rest of the molecule by single bonds. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of polycyclic cycloalkyls include adamantyl, norbornyl, dekalinyl, and 7,7-dimethylbicyclo-[2.2.1]heptanyl. Unless specifically described herein, cycloalkyl groups may be substituted.
[0026] "Aryl" refers to a ring system containing at least one carbocyclic aromatic ring. In some embodiments, the aryl contains 6 to 18 carbon atoms. The aryl ring may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include condensed or bridging ring systems. Examples of aryls include aryls derived from acetantrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluorantene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless specifically described herein, the aryl group may be substituted.
[0027] A "heterocyclic" refers to a stable 3- to 18-membered aromatic or non-aromatic ring containing 1 to 12 carbon atoms and 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Unless otherwise specifically described herein, heterocyclic rings may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused or bridging ring systems, and the nitrogen, carbon, or sulfur atoms of the heterocyclic ring may be oxidized, the nitrogen atom may be quaternized, and the heterocyclic ring may be partially or completely saturated. Examples of aromatic heterocyclic rings are listed below in the definition of heteroaryls (i.e., heteroaryls, which are a subset of heterocyclic rings). Examples of non-aromatic heterocyclic rings include, for example, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2oxopiperazinyl, 2oxopiperidinyl, 2oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4piperidonyl, pyrrolidinyl, pyrazolidinyl, pyrazolopyrimidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trioxanyl, trithianyl, triazinyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1oxothiomorpholinyl, and 1,1-dioxothiomorpholinyl. Unless specifically described herein, heterocyclic groups may be substituted.
[0028] "Heteroaryl" refers to a 5-14 membered ring system comprising 1-6 heteroatoms selected from the group consisting of 1-13 carbon atoms, nitrogen, oxygen, and sulfur, and at least one aromatic ring. For the purposes of certain embodiments of the present invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include condensed or bridging ring systems, and the nitrogen, carbon, or sulfur atoms of the heteroaryl radical may be oxidized, and the nitrogen atom may be quaternized.Examples include, for instance, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzoindolyl, benzodioxolyl, benzofuranil, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanil, benzonaphthofuranil, benzoxazolyl, benzodioxolyl, benzodioxynil, benzopyranil, benzopyranonil, benzofuranil, benzofuranonil, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2a]pyridinil, benzoxazolinonil, benzimidazolethionil, carbazolyl, sinnolinil, dibenzofuranil, dibenzothiophenyl, furanil, furanonil, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolidinil Isooxazolyl, naphthilidinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxyranil, 1-oxidepyridinyl, 1-oxidepyrimidinyl, 1-oxidepyradinyl, 1-oxidepyridazinyl, 1-phenyl-1H-pyrrolyl, phenadinyl, phenothiazinyl, phenoxadinyl, phthalazinyl, pteridinyl, pteridinonyl, prinyl, pyrrolyl, pyrazolyl, pyridinyl, pyridinonyl, pyradinyl, pyrimidinyl, p These include lilymidinonyl, pyridadinyl, pyrrolyl, pyrido[2,3-d]pyrimidinonyl, quinazolinyl, quinazolinyl, quinoxalinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, thieno[3,2-d]pyrimidine-4-onyl, thieno[2,3-d]pyrimidine-4-onyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless specifically described herein, heteroaryl groups may be substituted. "Condensation" refers to a ring system containing at least two rings, where the two rings share at least one common ring atom, for example, two common ring atoms. If the fused ring is a heterocyclyl ring or a heteroaryl ring, the common ring atom may be carbon or nitrogen. Condensed rings include bicyclic, tricyclic, and tetracyclic rings.
[0029] As used herein, the term "substituted" means that at least one hydrogen atom (e.g., one, two, three, or all hydrogen atoms) is replaced by, for example, halogen atoms, e.g., F, Cl, Br, and I; oxygen atoms in groups such as hydroxyl groups, alkoxy groups, and ester groups; sulfur atoms in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; nitrogen atoms in groups such as amines, amides, alkylamines, zylylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; trialkylsilyl groups, dialkylarylsilyl groups, alkyl "Substituted" means any of the above groups (e.g., alkyl, alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, alkoxy, alkyl ether, alkoxyalkyl ether, heteroalkyl, heteroalkoxy, phosphoalkyl, phosphoalkyl ether, thiophosphoalkyl, thiophosphoalkyl ether, carbocyclic, cycloalkyl, aryl, heterocyclic, and / or heteroaryl) in which one or more hydrogen atoms are replaced by a heteroatom, e.g., oxygen in oxo, carbonyl, carboxyl, and ester groups, and nitrogen in imine, oxime, hydrazone, and nitrile groups (e.g., double or triple bonds). For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced by -NRgRh, -NRgC(=O)Rh, -NRgC(=O)NRgRh, -NRgC(=O)ORh, -NRgSO2Rh, -OC(=O)NRgRh, -ORg, -SRg, -SORg, -SO2Rg, -OSO2Rg, -SO2ORg, =NSO2Rg, and SO2NRgRh. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRh, -CH2SO2Rg, and -CH2SO2NRgRh.In the foregoing, Rg and Rh are the same or different, independently of hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, and / or heteroarylalkyl. "Substituted" further means any of the above groups in which one or more hydrogen atoms are replaced by bonding to amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, and / or heteroarylalkyl. In some embodiments, any substituent is -OP(=Ra)(Rb)Rc (wherein Ra, Rb, and Rc are as defined for the compound of structure (I)). In addition, each of the aforementioned substituents may also be substituted with one or more of the above substituents. "Conjugation" refers to the overlap of one p-orbital across an intervening sigma bond with another p-orbital. Conjugation can occur in cyclic or acyclic compounds. "Degree of conjugation" refers to the overlap of at least one p-orbital across an intervening sigma bond with another p-orbital. For example, 1,3-butadiene has a degree of conjugation of 1, while benzene and other aromatic compounds typically have multiple degrees of conjugation. Fluorescent and colored compounds typically contain at least one degree of conjugation. "Fluorescence" refers to molecules that can absorb light of a specific frequency and emit light of a different frequency. Fluorescence is well known to those skilled in the art. "Coloring" refers to molecules that absorb light within the colored spectrum (i.e., red, yellow, blue, etc.).
[0030] "FRET," which refers to Forster resonance energy transfer, refers to a physical interaction in which energy originating from the excitation of one part (e.g., the first chromophore or "donor") is transferred to an adjacent part (e.g., the second chromophore or "acceptor"). "FRET" is also sometimes used interchangeably with fluorescence resonance energy transfer (i.e., when each chromophore is a fluorescent part). Generally, FRET requires that (1) the excitation or absorption spectrum of the acceptor chromophore overlaps with the emission spectrum of the donor chromophore, (2) the transition dipole moments of the acceptor and donor chromophore are substantially parallel (i.e., about 0° or 180°), and (3) the acceptor and donor chromophore share spatial proximity (i.e., are close to each other). The energy transfer from donor to acceptor occurs through non-radiative dipole-dipole coupling, and generally, the distance between the donor and acceptor chromophore is much shorter than the wavelength of light.
[0031] A "donor" or "donor chromophore" refers to a chromophore (e.g., a fluorophore) that is in an excited electronic state or can be induced into one, and its excitation energy can be transferred to a nearby acceptor chromophore in a non-radiative manner via long-range dipole-dipole interactions. While we do not wish to be constrained by theory, it is thought that energy transfer occurs because the vibrational dipoles of individual chromophores have similar resonance frequencies. These donors and acceptors with similar resonance frequencies, referred to as "donor-acceptor pairs," are used interchangeably with "FRET moieties" or "FRET dyes." An "acceptor" or "acceptor chromophore" refers to a chromophore (e.g., a fluorophore) whose excitation energy originating from a donor chromophore is transferred via non-radiative transport through long-range dipole-dipole interactions. "Stokes shift" refers to the difference (e.g., wavelength) between the positions of the band maxima in the absorption and emission spectra of an electronic transition (e.g., from an excited state to a non-excited state, or vice versa). In some embodiments, the compound has a Stokes shift of greater than 25 nm, greater than 30 nm, greater than 35 nm, greater than 40 nm, greater than 45 nm, greater than 50 nm, greater than 55 nm, greater than 60 nm, greater than 65 nm, greater than 70 nm, greater than 75 nm, greater than 80 nm, greater than 85 nm, greater than 90 nm, greater than 95 nm, greater than 100 nm, greater than 110 nm, greater than 120 nm, greater than 130 nm, greater than 140 nm, greater than 150 nm, greater than 160 nm, greater than 170 nm, greater than 180 nm, greater than 190 nm, or greater than 200 nm. A "linker" refers to a continuous chain of at least one atom, such as carbon, oxygen, nitrogen, sulfur, phosphorus, or combinations thereof, which connects a part of a molecule to another part of the same molecule, or to different molecules, parts, or solid supports (e.g., microparticles). Linkers may connect molecules through covalent bonds or other means, such as ionic bonds or hydrogen bonds. As used herein, “nucleic acid,” “nucleic acid molecule,” or “polynucleotide” means either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), and includes oligonucleotides.
[0032] Nucleic acids can represent a coding chain or its complement. Nucleic acids may consist of monomers that are naturally occurring nucleotides (e.g., deoxyribonucleotides and ribonucleotides), analogs of naturally occurring nucleotides (e.g., α-enantiomers of naturally occurring nucleotides), or combinations of both. Nucleic acids in nucleic acid sequences are named according to standard IUPAC rules. Specifically, "A" is adenine, "C" is cytosine, "G" is guanine, "T" is thymine, and "U" is uracil, which refer to the following structures. [ka]
[0033] The sequence of a polynucleotide refers to the order in which nucleotides are arranged within the polynucleotide. Analogues of naturally occurring nucleotides, also called modified nucleotides, may have modifications or substitutions in the sugar moiety or the pyrimidine or purine base moiety. Nucleic acid monomers may be linked by phosphodiester bonds or analogues of such bonds. Analogues of phosphodiester bonds include phosphorothioates, phosphorodithioates, phosphoroselenoates, phosphorodiselenoates, phosphoranilothioates, phosphoranilidetes, and phosphoramidates. Modified internucleotide bonds are used in various embodiments. Modified internucleotide bonds are well known in the art and include methylphosphonates, phosphorothioates, phosphorodithioates, phosphoramidites, and phosphate ester bonds. Nucleic acid molecules may be single-stranded or double-stranded.
[0034] Naturally occurring nucleotide analogs further include locked nucleic acids (LNA), also known as cross-linked nucleic acids (BNA). LNA contains a 2'-oxygen,4'-carbon methylene crosslink that "locks" the 3'-end conformation, thereby limiting the flexibility of the ribofuranose ring. The term “hybridization,” as used herein, refers to any method by which a first strand of nucleic acid is joined to a second strand of nucleic acid via base pairing. Hybridization can occur between perfectly complementary nucleic acid strands or between “substantially complementary” nucleic acid strands containing minute mismatch regions. For ease of understanding, hybridization will generally be discussed herein with reference to a double-stranded structure (i.e., the structure of two nucleic acids), but those skilled in the art will understand that the embodiments described below also encompass arrangements in which the nucleic acids are described from a triple-stranded structure (i.e., the structure of three nucleic acids). For example, two probes may hybridize to a single target sequence, or two detectable probes may hybridize to the same region of a capture probe. When used herein, a probe is a polynucleotide that is "specific" to a target sequence if, when used under sufficiently strict conditions, the probe hybridizes primarily to the target nucleic acid only. Typically, a probe is specific to a target sequence if the probe-target double (or triple) strand stability is greater than the stability of the double (or triple) strand formed between the probe and any other sequences found in the sample. Those skilled in the art will recognize that various factors, such as the salt state, as well as the base composition and mismatch location of the probe, affect the specificity of the probe, and that routine experiments to confirm the specificity of the probe are necessary in most cases. Hybridization conditions can be selected so that the probe forms a stable double (or triple) strand only with the target sequence. Thus, the use of a target-specific probe under appropriately strict conditions allows for the specific amplification of the target sequence containing the target probe binding site. The use of sequence-specific conditions allows for the specific binding of the probe to a target sequence containing a precisely complementary probe binding site.
[0035] Conditions under which only perfectly complementary nucleic acid chains hybridize are referred to as “strict hybridization conditions” or “sequence-specific hybridization conditions.” The term “strict,” as used herein, refers to hybridization conditions that are generally understood in the art to define the conditions of a hybridization process. Conditions of strictness can be low, high, or moderate, and these terms are generally known in the art and well understood by those skilled in the art. In various embodiments, strict conditions may include, for example, highly strict conditions and / or mildly strict (i.e., moderately strict) conditions. Stable double (or triple) strands with substantially complementary sequences can be achieved under less stringent hybridization conditions, and the acceptable degree of mismatch can be controlled by appropriate adjustment of the hybridization conditions. Those skilled in nucleic acid technology can determine double (or triple) strand stability according to the guidelines provided in the art by empirically considering numerous variability factors, including, for example, the length and base pair composition of oligonucleotides, ionic strength, and the rate of mismatch base pair occurrence.
[0036] As used herein, “complementary” refers to a nucleic acid molecule that can form hydrogen bonds with another nucleic acid molecule either through traditional Watson-Crick base pairing between complementary nucleosides or nucleotides, or through other non-traditional types of pairing (e.g., Hougsteen or inverse Hougsteen hydrogen bonding). It is understood in the art that nucleic acid molecules do not need to be 100% complementary to the target nucleotide sequence to which they can be specifically hybridized. That is, two or more nucleic acid molecules do not need to be perfectly complementary and are indicated by the percentage of consecutive residues in the nucleic acid molecule that can form hydrogen bonds with the second nucleic acid molecule. For example, if the first nucleic acid molecule has 10 nucleotides and the second nucleic acid molecule has 10 nucleotides, the base pairing of 5 out of 5, 6, 7, 8, 9, or 10 nucleotides between the first and second nucleic acid molecules represents 50%, 60%, 70%, 80%, 90%, and 100% complementarity, respectively. "Perfectly" or "fully" complementary nucleic acid molecules mean that all consecutive residues of the first nucleic acid molecule are hydrogen-bonded to the same number of consecutive residues of the second nucleic acid molecule, where both nucleic acid molecules have the same number of nucleotides (i.e., the same length), or the two molecules have different lengths.
[0037] The term “hybridization complex,” as used herein, refers to a complex formed between two nucleotide sequences thanks to the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases, which may be further stabilized by base stacking interactions. The two complementary nucleotide sequences are hydrogen-bonded in an antiparallel configuration. The hybridization complex may be formed in solution (e.g., Cot or Rot analysis), or between one nucleotide sequence present in solution and another nucleotide sequence immobilized on a solid support (e.g., paper, membrane, filter, tip, pin, or glass slide, or any other suitable substrate on which cells and / or nucleic acids are immobilized). A "reactive group" is a moiety that can react with a second reactive group (e.g., a "complementary reactive group") to form one or more covalent bonds, for example, by substitution, redox, addition, or cyclic addition reactions. Exemplary reactive groups include, for example, nucleophiles, electrophiles, dienes, dienophiles, aldehydes, oximes, hydrazones, alkynes, amines, azides, acyl azides, acyl halides, nitriles, nitrones, sulfhydryls, disulfides, sulfonyl halides, isothiocyanates, imide esters, activated esters, ketones, α,β-unsaturated carbonyls, alkenes, maleimides, α-haloimides, epoxides, aziridines, tetrazines, tetrazoles, phosphines, biotins, and thiiranes.
[0038] The terms “visible” and “visually detectable” are used herein to refer to substances that can be observed by visual inspection without prior illumination or chemical or enzymatic activation. Such visually detectable substances absorb and emit light in the spectral region in the range of about 300 to about 900 nm. Preferably, such substances are densely colored and have a molar extinction coefficient of at least about 40,000, more preferably at least about 50,000, even more preferably at least about 60,000, still more preferably at least about 70,000, and most preferably at least at least about 80,000 M⁻¹cm⁻¹. The compounds of the present invention can be observed and detected by the naked eye or with the help of optically based detection devices, including but not limited to absorption spectrophotometers, transmission light microscopes, digital cameras and scanners. Visually detectable substances are not limited to those that emit and / or absorb light in the visible spectrum. Substances that emit and / or absorb light in the ultraviolet (UV) region (approximately 10 nm to 400 nm) and the infrared (IR) region (approximately 700 nm to 1 mm), as well as substances that emit and / or absorb light in other ranges of the electromagnetic spectrum, are included in the range of substances that are "visually detectable."
[0039] For the purposes of embodiments of the present invention, the term “photostable visible dye” means a chemical portion that is visually detectable as defined herein and does not significantly change or decompose when exposed to light. Preferably, a photostable visible dye does not show significant fading or decomposition after exposure to light for at least 1 hour. More preferably, the visible dye is stable after exposure for at least 12 hours, even more preferably at least 24 hours, even more preferably at least 1 week, and most preferably at least 1 month. Non-limiting examples of photostable visible dyes suitable for use in the compounds and methods of the present invention include azo dyes, thioindigo dyes, quinacridone pigments, dioxazines, phthalocyanines, perinones, diketopyrrolopyrroles, quinophthalones, and truarycarbonium. As used herein, the term “perylene derivative” is intended to include any substituted perylene that is visually detectable. However, the term is not intended to include perylene itself. The terms “anthracene derivative,” “naphthalene derivative,” and “pyrene derivative” are used similarly. In some preferred embodiments, the derivative (e.g., perylene, pyrene, anthracene, or naphthalene derivative) is an imide, bisimide, or hydrazamimide derivative of perylene, anthracene, naphthalene, or pyrene.
[0040] The visually detectable molecules of various embodiments of the present invention are useful for a wide variety of analytical applications, such as biochemical and biomedical applications where it is necessary to determine the presence, location, or quantity of a specific analyte (e.g., a biomolecule). Therefore, in another embodiment, the present invention provides a method for visually detecting a biomolecule, comprising the steps of (a) preparing a biological system having a visually detectable biomolecule containing a compound of formula (I) linked to the biomolecule, and (b) detecting the biomolecule by its visible properties. For the purposes of the present invention, the phrase "detecting a biomolecule by its visible properties" means that the biomolecule is observed without illumination or chemical or enzymatic activation, either by the naked eye or with the help of an optical-based detection device, including but not limited to absorption spectrophotometers, transmission optical microscopes, digital cameras, and scanners. A concentration meter may be used to quantify the amount of visually detectable biomolecule present. For example, the relative amounts of biomolecules in two samples can be determined by measuring their relative optical density. If the theoretical amount of dye molecules per biomolecule is known and the extinction coefficient of the dye molecules is known, the absolute concentration of the biomolecule can also be determined from the measurement of optical density. As used herein, the term “biological system” is used to refer to any solution or mixture containing one or more biomolecules in addition to biomolecules that are visible to the naked eye. Examples of such biological systems include cells, cell extracts, tissue samples, electrophoretic gels, assay mixtures, and hybridization reaction mixtures.
[0041] "Solid support" refers to any solid substrate known in the art for solid-phase supports of molecules, for example, "fine particles" refers to any number of small particles useful for binding to the compound of the present invention, for example, glass beads, magnetic beads, polymer beads, nonpolymer beads, etc. In certain embodiments, the fine particles include polystyrene beads. A "reside residue" refers to a functional group that remains attached to a molecule when the molecule is cleaved from its solid support. Reside residues are well known in the art and can be readily derived based on the structure of the solid support and the groups linking the molecule to it.
[0042] The word “target,” as used herein, refers to the analyte of interest to be detected. “Targeted moiety” is a moiety that selectively binds to or associates with a particular target, e.g., an analyte molecule. “Selectively” binding or associating means that the targeted moiety preferentially associates with or binds to the desired target compared to other targets. In some embodiments, the compounds disclosed herein include binding to a targeted moiety for the purpose of selectively binding to or associating with a compound having the analyte of interest (i.e., the target of the targeted moiety), thereby enabling the detection of the analyte. Exemplary targeted moieties include, for example, antibodies, antigens, nucleic acid sequences, enzymes, proteins, cell surface receptor antagonists, and the like. In some embodiments, the targeted moiety is a moiety, e.g., an antibody, that selectively binds to or associates with a target feature of a cell, e.g., a target feature of the cell membrane or other cellular structure, thereby enabling the detection of the cell of interest. Small molecules that selectively bind to or associate with a desired analyte are also considered targeted moieties in certain embodiments. Those skilled in the art will understand that other analytes and corresponding targeted moieties are useful in various embodiments. A "base-pairing moiety" refers to a heterocyclic moiety that can hybridize with a complementary heterocyclic moiety via hydrogen bonding (e.g., Watson-Crick base pairing). Base-pairing moieties include both native and non-native bases. Non-limiting examples of base-pairing moieties include RNA and DNA bases, such as adenosine, guanosine, thymidine, cytosine, and uridine, as well as their analogues.
[0043] As used herein, “capture probe” is a single-stranded DNA molecule bound to a solid support or targeting region (e.g., covalently or hybridized). Generally, the single-stranded DNA molecule contains a repeating nucleotide sequence complementary to the nucleotide sequence of the detectable probe or branched linker, so that multiple detectable probes or branched linkers can hybridize to a single capture probe. A "detectable linker" contains a nucleotide sequence bound to at least one chromophore.
[0044] As used herein, “branched linker” refers to a polymer backbone to which multiple polynucleotides are bound so that the polynucleotides extend away from the polymer backbone. For example, a branched linker may be a polyalkylene conjugated to multiple DNA molecules. The multiple polynucleotides include at least one polynucleotide having a first sequence, the first sequence being complementary to the repeating nucleotide sequence of the capture probe. Furthermore, the multiple polynucleotides include multiple polynucleotides having a second sequence, which is complementary to the nucleotide sequence of the detectable probe.
[0045] The embodiments disclosed herein are also intended to encompass all compounds of structure (I), (II), or (III) in which one or more atoms are isotoped and labeled by replacing them with atoms having different atomic masses or mass numbers. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, e.g., 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I, and 125I, respectively. Isotope-labeled compounds of structure (I) or (II) can generally be prepared by means of the prior art known to those skilled in the art, or by using a suitable isotope-labeling reagent instead of a previously used unlabeled reagent, in a manner similar to that described in the following examples. The terms "stable compound" or "stable structure" are intended to refer to a compound that is rigid enough to be isolated from a reaction mixture to a useful degree of purity and to remain in the formulation of an effective therapeutic agent. "Optional" or "optionally" means that the event or situation described thereafter may or may not occur, and that the description includes both cases in which the event or situation occurs and cases in which it does not occur. For example, "optionally substituted alkyl" means that the alkyl group may or may not be substituted, and that the description includes both substituted alkyl groups and unsubstituted alkyl groups.
[0046] The term "salt" includes addition salts of both acids and bases. "Acid addition salts" include salts formed from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids, such as acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cycloic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, This refers to salts formed from glutaric acid, 2-oxo-glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucoic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.
[0047] A "base addition salt" refers to a salt prepared by adding an inorganic or organic base to a free acid. Salts derived from inorganic bases include, for example, salts of sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Salts derived from organic bases include, for example, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydravamin, choline, betaine, benetamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, and polyamine resins. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0048] Crystallization can produce solvates of the compounds described herein. Embodiments of the present invention include all solvates of the compounds described herein. As used herein, the term “solvate” refers to an aggregate comprising one or more molecules of the compound of the present invention and one or more solvent molecules. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, and the corresponding solvated forms. The compounds of the present invention may be true solvates, while in other cases the compounds of the present invention may simply retain exogenous water or another solvent, or a mixture of water and some exogenous solvent.
[0049] Embodiments of the compounds of the present invention (e.g., compounds of structure I, II, or III), or their salts, tautomers of tautomers, or solvates, may contain one or more chiral centers, thereby giving rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined as (R) or (S) with respect to absolute stereochemistry, or as (D) or (L) in amino acids. Embodiments of the present invention are intended to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R) and (S), or (D) and (L) isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using prior art, e.g., chromatography and fractional crystallization. Prior art for preparing / isolating individual enantiomers includes chiral synthesis from suitable optically pure precursors, or resolution of racemic compounds (or salts or derivatives of racemic compounds) using, for example, chiral high-pressure liquid chromatography (HPLC). Unless otherwise specified, the compounds described herein contain olefinic double bonds or other geometrically asymmetric centers, and these compounds are intended to include both E and Z geometric isomers. Similarly, all tautomer forms are also intended to be included.
[0050] A "stereoisomer" refers to a compound that is composed of the same atoms bonded together by the same bonds, but has different three-dimensional structures that are not interchangeable. This invention considers various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are nonsuperimposeable mirror images of each other. "Tautomerism" refers to the transfer of a proton from one atom of a molecule to another atom of the same molecule. This invention includes tautomers of any compound. Various tautomer forms of compounds can be easily derived by those skilled in the art. The chemical nomenclature protocols and structural diagrams used herein are modified forms of IUPAC nomenclature using the ACD / Name Version 9.07 software program and / or the ChemDraw Ultra Version 11.0 software nomenclature program (CambridgeSoft). Common names well known to those skilled in the art are also used.
[0051] As previously stated, one embodiment of the present invention provides a compound useful as a probe in various analytical methods. In general terms, the embodiments of this application relate to a compound that can be used as a capture probe or a detectable probe, and a composition containing the same. In some embodiments, the compounds of the present disclosure have the following structure (I) or stereoisomers, salts, or tautomers thereof. [ka] (I) (In the formula, M is the same or different chromophore in each occurrence, independently. L 1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L 3 , L 5 , L 6 and L 7 Each instance is independently any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 4 Each occurrence is independently alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. R 1 and R 2 R 1 and R 2If at least one of them contains a polynucleotide, then each can be independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , or a portion containing polynucleotides, R 3 In each occurrence, it is independently H, alkyl, or alkoxy. R 4 In each occurrence, OH, SH, and O appear independently. - S - , OR d or SR d And, R 5 In each occurrence, independently, it is either oxo, thioxo, or absent. R a is either O or S, R b OH, SH, O - S - , OR d or SR d And, R c OH, SH, O - S - , OR d ,OL',SR d Alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 1, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0052] In some embodiments, M is the same or different donor chromophore independently in each appearance. In other embodiments, M is the same or different acceptor chromophore independently in each appearance. In a particular embodiment, M is the same donor chromophore in each appearance. In other embodiments, M is the same acceptor chromophore in each appearance. In some embodiments, M is the same or different fluorophore independently in each occurrence. In some embodiments, M is the same or different donor fluorophore independently in each occurrence. In other embodiments, M is the same or different acceptor fluorophore independently in each occurrence. In some particular embodiments, M is the same donor fluorophore in each occurrence. In other embodiments, M is the same acceptor fluorophore in each occurrence.
[0053] In some embodiments, R 1 and R 2 These are, respectively, parts containing polynucleotides. In some such embodiments, R 1 The polynucleotide is the R of the first compound. 1 The polynucleotide of the second compound R 2 R 2 It is complementary to the polynucleotide. An example of this is illustrated in Figure 3A. The targeting portion 301 (in this case, the coated bead) is bound to the first polynucleotide 320. Probes 305a, 305b, 305c, and 305d are independently compounds of formula (I). Each of the probes independently contains polymers 314a, 314b, 314c, and 314d, which are positioned between the second polynucleotides 316a, 316b, 316c, and 316d and the third polynucleotides 317a, 317b, 317c, and 317d. As shown in Figure 3A, the second polynucleotide 316b of probe 305b hybridizes with the third polynucleotide 317a of probe 305a. In some embodiments, a triple-stranded structure is formed by the polynucleotides of the three probes.
[0054] In some embodiments, the second sequence has at least 92% complementarity with the third sequence. In some embodiments, the second sequence has at least 95% complementarity with the third sequence. In some embodiments, the second sequence has at least 96% complementarity with the third sequence. In some embodiments, the second sequence has at least 97% complementarity with the third sequence. In some embodiments, the second sequence has at least 98% complementarity with the third sequence. In some embodiments, the second sequence has at least 99% complementarity with the third sequence. Furthermore, in some embodiments, the probes include two or more probes 305, 307 in an alternating or repeating pattern (as shown in Figure 3B). In some such embodiments, each of the first probes 305 independently includes a polymer 314 positioned between a second polynucleotide 316 and a third polynucleotide 317, and each of the second probes 307 includes a polymer 314 positioned between a fourth polynucleotide 319 and a fifth polynucleotide 321. The third polynucleotide 317 hybridizes with the fourth polynucleotide 319, and the fifth polynucleotide 321 hybridizes with the second polynucleotide. In some embodiments, a triple-stranded structure is formed by the polynucleotides of the three probes.
[0055] In some embodiments, each of the first polymers contains a plurality of chromophores. In embodiments, the second polynucleotide, the third polynucleotide, or both have a length in the range of 10 to 40 nucleotides. In some embodiments, the second polynucleotide, the third polynucleotide, or both have a length in the range of 10 to 30 nucleotides. In some embodiments, the second polynucleotide, the third polynucleotide, or both have a length in the range of 15 to 25 nucleotides.
[0056] One of the second polynucleotides hybridizes with the first polynucleotide. In various embodiments, the first polynucleotide has a first sequence that is at least 90% complementary to the second sequence. In some embodiments, the first sequence is at least 92% complementary to the second sequence. In some embodiments, the second sequence is at least 95% complementary to the first sequence. In some embodiments, the second sequence is at least 96% complementary to the first sequence. In some embodiments, the second sequence is at least 97% complementary to the first sequence. In some embodiments, the second sequence is at least 98% complementary to the first sequence. In some embodiments, the second sequence is at least 99% complementary to the first sequence. In other embodiments, the targeting moiety is covalently bound to the capture probe.
[0057] In other embodiments, the compounds of the present disclosure have the following structure (II) or stereoisomers, salts, or tautomers thereof. [ka] (II) (In the formula, M is an independent chromophore in each appearance. L 1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L 3 , L 5 , L 6 and L 7 Each instance is independently any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 4 Each occurrence is independently alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 9It is a linker containing polynucleotides, R 1 and R 2 These are, independently, H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, or -OP(=R a )(R b )R c And, R 3 In each occurrence, it is independently H, alkyl, or alkoxy. R 4 In each occurrence, OH, SH, and O appear independently. - S - , OR d or SR d And, R 5 In each occurrence, independently, it is either oxo, thioxo, or absent. R a is either O or S, R b OH, SH, O - S - , OR d or SR d And, R c OH, SH, O - S - , OR d ,OL',SR d Alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 1, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0058] In some embodiments, M is the same or different donor chromophore independently in each appearance. In other embodiments, M is the same or different acceptor chromophore independently in each appearance. In a particular embodiment, M is the same donor chromophore in each appearance. In other embodiments, M is the same acceptor chromophore in each appearance. In some embodiments, M is the same or different fluorophore independently in each occurrence. In some embodiments, M is the same or different donor fluorophore independently in each occurrence. In other embodiments, M is the same or different acceptor fluorophore independently in each occurrence. In some particular embodiments, M is the same donor fluorophore in each occurrence. In other embodiments, M is the same acceptor fluorophore in each occurrence.
[0059] In some embodiments, the compounds of the present disclosure have the following structures (IIa) or (IIb), or stereoisomers, salts, or tautomers thereof. [ka] (In the formula, M 1 Each appearance independently involves the same or different donor chromophores. M 2 These are, independently in each appearance, the same or different acceptor chromophores. L 1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L 3 , L 5 , L 6 and L 7Each instance is independently any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 4 Each occurrence is independently alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 9 It is a linker containing polynucleotides, R 1 and R 2 These are, independently, H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, or -OP(=R a )(R b )R c And, R 3 In each occurrence, it is independently H, alkyl, or alkoxy. R 4 In each occurrence, OH, SH, and O appear independently. - S - , OR d or SR d And, R 5 In each occurrence, independently, it is either oxo, thioxo, or absent. R a is either O or S, R b OH, SH, O - S - , OR d or SR d And, R c OH, SH, O - S - , OR d ,OL',SR d Alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 1, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0060] In some embodiments, the compounds of the disclosure have structure (IIa). In some embodiments, the compounds of the disclosure have structure (IIb). In some embodiments, M 1 In each occurrence, independently, the donor fluorophores are the same or different. In other embodiments, M 2 In each occurrence, independently, the acceptor fluorophores are the same or different. In a particular embodiment, M 1 In each occurrence, M is the same donor fluorophore. In other embodiments, M 2 This is the same acceptor fluorophore in each occurrence.
[0061] In this embodiment, L 9 The polynucleotides have lengths ranging from 10 to 40 nucleotides. In some embodiments, L 9 The polynucleotides have lengths ranging from 10 to 30 nucleotides. In some embodiments, L 9 The polynucleotides have lengths ranging from 15 to 25 nucleotides. In some embodiments, compounds described herein having structures (I), (II), (IIa), (IIb), or combinations thereof are detectable probes. In some embodiments, compounds described herein having structure (I) are detectable probes. In some embodiments, compounds described herein having structure (II) are detectable probes. In some embodiments, compounds described herein having structure (IIa) are detectable probes. In some embodiments, compounds described herein having structure (IIb) are detectable probes.
[0062] Therefore, in some embodiments, the compounds of the present disclosure have the following structure (III) or stereoisomers, salts, or tautomers thereof. [ka] (III) (In the formula, M is the same or different chromophore in each occurrence, independently. L 1a In each occurrence, it is independently a heteroarylene linker. L 2 and L 8 It is an independent, arbitrary linker, L 1b , L 3 , L 5 , L 6 and L 7 Each instance is independently any alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 4 Each occurrence is independently alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkylynylene linker. L 10 It is a linker containing polynucleotides, R 1 and R 2 R 1 and R 2If at least one of them contains a polynucleotide, then each can be independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , or a portion containing polynucleotides, R 3 In each occurrence, it is independently H, alkyl, or alkoxy. R 4 In each occurrence, OH, SH, and O appear independently. - S - , OR d or SR d And, R 5 In each occurrence, independently, it is either oxo, thioxo, or absent. R a is either O or S, R b OH, SH, O - S - , OR d or SR d And, R c OH, SH, O - S - , OR d ,OL',SR d Alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether or thiophosphoalkyl ether, R d It is a counterion, L' is independently a linker containing a covalent bond to a solid support, a linker containing a covalent bond to a solid support residue, or a linker containing a covalent bond to a nucleoside in each occurrence. m is a non-zero integer, independently in each occurrence. n is an integer greater than or equal to 2, q and w are either 0 or 1 in each occurrence, if at least one occurrence of either q or w is 1.
[0063] In some embodiments, M is the same or different donor chromophore independently in each appearance. In other embodiments, M is the same or different acceptor chromophore independently in each appearance. In a particular embodiment, M is the same donor chromophore in each appearance. In other embodiments, M is the same acceptor chromophore in each appearance. In some embodiments, M is the same or different fluorophore independently in each occurrence. In some embodiments, M is the same or different donor fluorophore independently in each occurrence. In other embodiments, M is the same or different acceptor fluorophore independently in each occurrence. In some particular embodiments, M is the same donor fluorophore in each occurrence. In other embodiments, M is the same acceptor fluorophore in each occurrence. In this embodiment, R 1 It contains polynucleotides. In some embodiments, R 2 It contains polynucleotides. In a specific embodiment, R 1 It includes a targeting moiety bound to a polynucleotide. In a specific embodiment, R 2 It contains a targeting moiety bound to a polynucleotide. In this embodiment, the compound of structure (III) is a capture probe.
[0064] The polynucleotide in any of structures (I), (II), or (III) may end with any acceptable group if it is at the terminal end of the compound. For example, a particular polynucleotide may end with either a hydroxyl group or a phosphate group. In various other embodiments, the polynucleotide may be -OP(=R a )(R b )R c And that's the end, R c is OL', R a and R bL' is as defined above. In some of these embodiments, L' is a heteroalkylene linker to a solid support, a solid support residue, or a nucleoside. In some embodiments, L' includes an oxidized alkylene or phosphodiester moiety, or a combination thereof. In certain embodiments, L' has the following structure: [ka] (In the formula, m'' and n'' are independent integers between 1 and 10. R e H is an electron pair or counterion, L is R e (or direct binding or linking to a solid support, solid support residue, or nucleoside (e.g., deoxythymidine))
[0065] In some embodiments, polynucleotides end in the following structure. [ka] (In the formula, dT is deoxythymidine.) [ka]
[0066] In the embodiment, each occurrence of q is 0. In the embodiment, at least one occurrence of q is 1. In the embodiment, each occurrence of w is 0. In the embodiment, at least one occurrence of w is 1. In the embodiment, each occurrence of q is 0. In the embodiment, L 4 At least one occurrence of is heteroalkylene, or L 4 Each occurrence is a heteroalkylene. In some embodiments, the heteroalkylene includes alkylene oxide. In other embodiments, the heteroalkylene includes ethylene oxide. In some embodiments, L 4 It has the following structure. [ka] (In the formula, z is an integer between 1 and 100. * (This indicates a bond to an adjacent phosphorus atom.)
[0067] In the embodiment, z is an integer between 3 and 6 or an integer between 22 and 26. In the embodiment, L 4 At least one occurrence of is alkylene, or L 4 Each occurrence is an alkylene. In various embodiments, at least one alkylene is ethylene, or each alkylene is ethylene. In further embodiments, R 3 At least one occurrence of is H or R 3 Each occurrence is H. In some embodiments, L 1a In each occurrence, independently, is a 5- to 7-membered ring heteroarylene linker which may be substituted. In the embodiment, L 1a It has one of the following structures. [ka]
[0068] In this embodiment, L 3 At least one occurrence of is an alkylene linker, or L 3 Each occurrence is an alkylene linker. 2 and / or L 8 At least one occurrence of L is absent, or 2 and / or L 8 Each occurrence is absent. In the embodiment, L 5 and / or L 6 At least one occurrence of is alkylene, or L 5 and / or L 6 Each occurrence is alkylene. In various embodiments, L 1b Each instance independently contains either an amide functional group or a triazolyl functional group. In this embodiment, R 5 In each occurrence, OH and O appear independently. - OR d In this embodiment, R 4is oxo at each occurrence.
[0069] In embodiments, L 7 at least one occurrence of is an optionally substituted heteroalkylene linker or each occurrence of L 7 is, independently, an optionally substituted heteroalkylene linker. In embodiments, L 7 contains an amide functional group or a triazolyl functional group. In some embodiments, each occurrence of L 7 has one of the following structures. [Chemical formula] In embodiments, n is an integer from 1 to 100 or n is an integer from 1 to 10, or 2 to 10. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In embodiments, m is an integer from 3 to 6 or m is 3.
[0070] In embodiments, the fluorophore is, independently at each occurrence, dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quarterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,10-ethynylanthracene or ter-naphthyl moiety. In embodiments, the fluorophore is, independently at each occurrence, pyrene, perylene, perylenemonoimide, 5-FAM or 6-FAM, or derivatives thereof. In further embodiments, the fluorophore is, independently at each occurrence, selected from Table 1. [Table 1] TIFF2023550791000019.tif250135 TIFF2023550791000020.tif249133 TIFF2023550791000021.tif254138 TIFF2023550791000022.tif140138
[0071] In certain embodiments, the fluorophore independently has, at each occurrence, one of the following structures.
Chemical formula
[0072] In an embodiment, the fluorophore independently has, at each occurrence, one of the following structures.
Chemical formula
[0073] The efficiency of the FRET process depends, in part, on the characteristics of the chromophores. Specifically, high-efficiency FRET requires a large overlap between the absorption spectrum of the donor chromophore and the emission spectrum of the acceptor chromophore. Furthermore, the distance and orientation of the chromophores play important roles. The FRET efficiency is inversely proportional to the sixth power of the distance between the chromophores, and the angle of the transition dipole moments must be substantially aligned (i.e., close to 0° or 180°). Thus, in certain embodiments, the covalent attachment of the first chromophore and the second chromophore to the polymer backbone is selected such that the distance between the first chromophore and the second chromophore is minimized and the transition dipole moments are substantially aligned. The efficiency of FRET is given by the following equation:
[0074]
number
number
[0075] In some embodiments, the effective distance between the acceptor chromophore and the donor chromophore is less than approximately 25.0 nm. In some embodiments, the effective distance between the acceptor chromophore and the donor chromophore is less than approximately 10.0 nm. In some embodiments, the effective distance between the acceptor chromophore and the donor chromophore is less than approximately 30.0 nm, less than approximately 27.0 nm, less than approximately 22.0 nm, less than approximately 20.0 nm, less than approximately 17.0 nm, less than approximately 15.0 nm, less than approximately 12.0 nm, less than approximately 11.0 nm, less than approximately 9.0 nm, less than approximately 8.0 nm, less than approximately 7.0 nm, less than approximately 6.0 nm, less than approximately 5.0 nm, less than approximately 4.0 nm, less than approximately 3.0 nm, less than approximately 2.0 nm, or less than approximately 1.0 nm. In some embodiments, the acceptor chromophore is a fluorescent dye portion. In certain embodiments, the donor chromophore is a fluorescent dye portion. In certain related embodiments, both the acceptor chromophore and the donor chromophore are fluorescent dye portions. In some embodiments, the angle between the acceptor transition dipole moment and the donor transition dipole moment is in the range of 120° to 180°. For example, in some embodiments, the angle between the acceptor transition dipole moment and the donor transition dipole moment is in the range of 125° to 180°, 130° to 180°, 140° to 180°, 150° to 180°, 160° to 180°, 170° to 180°, 172° to 180°, 175° to 180°, or 177° to 180°. In certain embodiments, the angle between the acceptor transition dipole moment and the donor transition dipole moment is in the range of 0° to 60°. For example, in some embodiments, the angle between the acceptor transition dipole moment and the donor transition dipole moment is in the range of 0° to 50°, 0° to 40°, 0° to 30°, 0° to 20°, 0° to 10°, 0° to 8°, 0° to 5°, 0° to 3°, or 0° to 2°.
[0076] In the embodiment, M 1 It is a donor chromophore, M 2 M is an acceptor chromophore. In such embodiments, M 1 and M 2 The element is selected based on desired optical properties, for example, based on desired Stokes shift, absorbance / emission overlap, specific color and / or fluorescence emission wavelength. In some embodiments, M 1 (or alternatively, M 2 ) is the same in each occurrence, however, M 1 Or M 2 Each occurrence is the same M 1 Or M 2 It is important to note that it does not necessarily have to be M. 1 The compounds included are not the same in each appearance. Some embodiments include M 2 This includes compounds that are not the same in each occurrence. In some embodiments, M 1 and M 2 The elements are selected to have absorbance and / or emission characteristics for use in the FRET method. For example, in such an embodiment, the FRET mechanism emits M of different wavelengths. 2 At one wavelength that induces emission from irradiation by M 1 Different M 1 and M 2 A portion is selected. Example M 1 and M 2 The parts can be appropriately selected by those skilled in the art based on the desired end use. Each individual M 1 and M 2 M 1 Or M 2 It can bond to the rest of the molecule from any position (i.e., atom) above. Those skilled in the art will understand M 1 Or M 2 It will recognize the means for binding to the rest of the molecule. An exemplary method is the “click” reaction described herein.
[0077] In some embodiments, M 1 Or M 2 is a FRET, a fluorescent or chromogenic moiety. Any fluorescent and / or chromogenic moiety may be used to form a FRET donor-acceptor pair, for example, those known in the art, and those typically used in colorimetric assays, UV assays, and / or fluorescence assays. In some embodiments, M 1 Or M 2 , or both, independently fluoresce or chromogenic in each appearance. M useful in various embodiments of the present invention 1 Or M 2Examples of parts include, for example, xanthene derivatives (e.g., fluorescein, rhodamine, Oregon Green, eosin, or Texas Red); cyanine derivatives (e.g., cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, or merocyanine); squaline derivatives and ring-substituted squalines, including Seta, SeTau, and Square dyes; naphthalene derivatives (e.g., dansyl and prodan derivatives); coumarin derivatives; oxadiazole derivatives (e.g., pyridyloxazole, nitrobenzooxadiazole, or benzo Examples of M moieties include xadiazole; anthracene derivatives (e.g., anthraquinones including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives such as Cascade Blue; oxazine derivatives (e.g., Nile Red, Nile Blue, Cresyl Violet, Oxazine 170); acridine derivatives (e.g., Proflavin, Acridine Orange, Acridine Yellow); arylmethine derivatives: Auramine, Crystal Violet, Malachite Green; and tetrapyrrole derivatives (e.g., Porfin, Phthalocyanine, or Bilirubin). Other exemplary M moieties include cyanine dyes, xanthate dyes (e.g., Hex, Vic, Nedd, Joe, or Tet); Yakima Yellow; Redmond Red; Tamra; Texas Red and Alexa Fluor® dyes.
[0078] In any further embodiment described above, M 1 Or M 2 , or both, independently in each occurrence, include three or more aryl or heteroaryl rings, or combinations thereof, for example, four or more aryl or heteroaryl rings, or combinations thereof, or even five or more aryl or heteroaryl rings, or combinations thereof. In some embodiments, M 1 Or M 2 , or both, independently contain six aryl or heteroaryl rings, or combinations thereof, in each occurrence. In further embodiments, the rings are fused. For example, in some embodiments, M 1 Or M 2, or both, independently include three or more fused rings, four or more fused rings, five or more fused rings, or even six or more fused rings in each occurrence. In some embodiments, M 1 Or M 2 , or both are ring-shaped. For example, in some embodiments, M 1 Or M 2 , or both are carbocyclic. In other embodiments, M 1 Or M 2 , or both are complex algebraic expressions. In yet another embodiment described above, M 1 Or M 2 , or both, independently include an aryl moiety in each occurrence. In some of these embodiments, the aryl moiety is polycyclic. In other, more specific examples, the aryl moiety is a condensed polycyclic aryl moiety, which may include at least three, at least four, or even more than four aryl rings. In other embodiments of any of the above compounds of structure (I), (II), (IA), (IB), (IC), (ID), or (IE), M 1 Or M 2 Each instance, or both, independently contains at least one heteroatom. For example, in some embodiments, the heteroatom is nitrogen, oxygen, or sulfur. In any of the further embodiments described above, M 1 Or M 2 , or both, independently contain at least one substituent in each appearance. For example, in some embodiments, the substituent is a fluoro, chloro, bromo, iodo, amino, alkylamino, arylamino, hydroxy, sulfhydryl, alkoxy, aryloxy, phenyl, aryl, methyl, ethyl, propyl, butyl, isopropyl, t-butyl, carboxy, sulfonate, amide, or formyl group.
[0079] In some of the more specific embodiments described above, M 1 Or M 2, or both, are, independently at each occurrence, dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quarterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squalene, squarylium, 9,10-ethynylanthracene or ter-naphthyl moieties. In other embodiments, M 1 or M 2 , or both, are, independently at each occurrence, p-terphenyl, perylene, azobenzene, phenazine, phenanthroline, acridine, thioxanthene, chrysene, rubrene, coronene, cyanine, perylene imide or perylene amide, or derivatives thereof. In even more embodiments, M 1 or M 2 , or both, are, independently at each occurrence, coumarin dyes, resorufin dyes, dipyrromethene boron difluoride dyes, ruthenium bipyridyl dyes, energy transfer dyes, thiazole orange dyes, polymethine or N-aryl-1,8-naphthalimide dyes. In certain embodiments, M 1 and M 2 are, independently at each occurrence, boron-dipyrromethene, rhodamine, cyanine, pyrene, perylene, perylene monoimide or 6-FAM, or derivatives thereof.
[0080] In even more embodiments of any of the above, M 1 is the same at each occurrence. In other embodiments, each M 1 is different. In even more embodiments, one or more M 1 are the same and one or more M 1 are different. In even more embodiments of any of the above, M 2 is the same at each occurrence. In other embodiments, each M2 They are different. In more embodiments, one or more M 2 These are the same, one or more M 2 They are different. In some embodiments, M 1 Or M 2 In each instance, either or both are independently boron-dipyromethene, rhodamine, cyanine, pyrene, perylene, perylene monoimide, or 6-FAM, or derivatives thereof. In some other embodiments, M 1 and M 2 Each occurrence independently possesses one of the following structures:
[0081] [ka]
[0082] As should be understood, the compounds described herein may be formed using any preferred method, such as the methods described in U.S. Patent Publication No. 2017 / 0292957, U.S. Patent Publication No. 2016 / 0208100, U.S. Patent Publication No. 2016 / 0341736, U.S. Patent Publication No. 2018 / 0065998, U.S. Patent Publication No. 2018 / 0079909, and U.S. Patent Publication No. 2019 / 0016898, which are incorporated by whole reference with respect to such teachings. Schematic types of explanatory capture probe 102 and explanatory detectable probes 104, 106 are shown in Figure 1. Capture probe 102 comprises (1) a first segment containing a first polynucleotide 108 having a first sequence, and (2) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of alternating second polynucleotides 110 and first polymers 112a, 112b, each of the first polymers containing a first chromophore 114, and each of the second polynucleotides containing a second sequence. In some embodiments, the capture probe is a compound of structure (III) described above.
[0083] Multiple detectable probes 104, 106 are also present, each of which contains a third polynucleotide 116 covalently bonded to at least one second polymer containing second chromophores 118a, 118b. In embodiments, the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence. Accordingly, compositions are described herein that include (1) a capture probe comprising a first segment comprising a first segment having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of alternating second polynucleotides and a first polymer, each of the first polymers comprising a first chromophore and each of the second polynucleotides comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a third polynucleotide covalently bonded to at least one second polymer comprising a second chromophore, wherein the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence.
[0084] In some embodiments, the second sequence has at least 92% complementarity with the third sequence. In some embodiments, the second sequence has at least 95% complementarity with the third sequence. In some embodiments, the second sequence has at least 96% complementarity with the third sequence. In some embodiments, the second sequence has at least 97% complementarity with the third sequence. In some embodiments, the second sequence has at least 98% complementarity with the third sequence. In some embodiments, the second sequence has at least 99% complementarity with the third sequence. In some embodiments, the triple-stranded structure is formed by two detectable probe polynucleotides and a capture probe polynucleotide. As shown in Figure 1, in some embodiments, each of the first polymers contains a plurality of first chromophores. Similarly, in some embodiments, each of the detectable probes contains a plurality of second chromophores. In some embodiments, the second polymers 118a, 118b are covalently bonded to each end of at least one third polynucleotide 116 of the detectable probe. In some embodiments, such as the embodiment shown in Figure 1, the first chromophore is an acceptor chromophore. In other embodiments, the first chromophore is a donor chromophore. As shown in Figure 1, in some embodiments, the second chromophore is a donor chromophore. In other embodiments, the second chromophore is a donor chromophore.
[0085] In some embodiments, the third polynucleotide has a length in the range of 10 to 40 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 10 to 30 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 15 to 25 nucleotides. In some embodiments, the third polynucleotide comprises a first portion, a second portion adjacent to the first portion, and a third portion separated from the first portion by the second portion. In some such embodiments, the third polynucleotide has complementarity with a portion of the second sequence to a higher degree than the degree of complementarity of the first portion to the third portion. Thus, the third polynucleotide preferentially hybridizes with the second sequence rather than forming a hairpin structure. In some embodiments, at least some of the detectable probes have the structures (I), (II), (IIa), (IIb) or combinations thereof described above. In some embodiments, at least one of the detectable probes has the structure (I) described above. In some embodiments, at least one of the detectable probes has the structure (II) described above. In some embodiments, at least one of the detectable probes has the structure (IIa) described above. In some embodiments, at least one of the detectable probes has the structure (IIb) described above.
[0086] In some embodiments, each detectable probe has one of the structures described above (I), (II), (IIa), (IIb), or a combination thereof. In some embodiments, each detectable probe has one of the structures described above (I). In some embodiments, each detectable probe has one of the structures described above (II). In some embodiments, each detectable probe has one of the structures described above (IIa). In some embodiments, each detectable probe has one of the structures described above (IIb).
[0087] As shown in Figure 1, the fourth polynucleotide 120 was covalently bonded to the targeting region 122. In other embodiments, the targeting region is covalently bonded to the capture probe. In embodiments, the composition includes a capture probe and a detectable probe as described herein. Thus, a composition is described herein that includes (1) a capture probe comprising a second segment comprising (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides each comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a third polynucleotide having a first and a second end, with at least one of the first and second ends covalently bonded to a first polymer comprising a chromophore, wherein the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence.
[0088] In some embodiments, the third polynucleotide has a length in the range of 10 to 40 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 10 to 30 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 15 to 25 nucleotides. In some embodiments, the second sequence has at least 92% complementarity with the third sequence. In some embodiments, the second sequence has at least 95% complementarity with the third sequence. In some embodiments, the second sequence has at least 96% complementarity with the third sequence. In some embodiments, the second sequence has at least 97% complementarity with the third sequence. In some embodiments, the second sequence has at least 98% complementarity with the third sequence. In some embodiments, the second sequence has at least 99% complementarity with the third sequence.
[0089] In some embodiments, each of the first polymers contains multiple chromophores. Similarly, in some embodiments, each of the second polymers contains multiple chromophores. In some embodiments, a second type of detectable probe is also present. In some such embodiments, the detectable probe contains a third polynucleotide bound to the first or second polymer. In some embodiments, at least a portion of the detectable probes have the structures (I), (II), (IIa), (IIb) described above, or a combination thereof. In some embodiments, at least one of the detectable probes has the structure (I) described above. In some embodiments, at least one of the detectable probes has the structure (II) described above. In some embodiments, at least one of the detectable probes has the structure (IIa) described above. In some embodiments, at least one of the detectable probes has the structure (IIb) described above. In some embodiments, each detectable probe has one of the structures described above (I), (II), (IIa), (IIb), or a combination thereof. In some embodiments, each detectable probe has one of the structures described above (I) (as illustrated in Figure 2A). In some embodiments, each detectable probe has one of the structures described above (II). In some embodiments, each detectable probe has one of the structures described above (IIa). In some embodiments, each detectable probe has one of the structures described above (IIb).
[0090] In some embodiments, the fourth polynucleotide is covalently bonded to the targeting moiety. In various embodiments, the fourth polynucleotide has a fourth sequence that is at least 90% complementary to the first sequence. In some embodiments, the fourth sequence is at least 92% complementary to the first sequence. In some embodiments, the fourth sequence is at least 95% complementary to the first sequence. In some embodiments, the fourth sequence is at least 96% complementary to the first sequence. In some embodiments, the fourth sequence is at least 97% complementary to the first sequence. In some embodiments, the fourth sequence is at least 98% complementary to the first sequence. In some embodiments, the fourth sequence is at least 99% complementary to the first sequence. In other embodiments, the targeting moiety is covalently bonded to the capture probe.
[0091] Schematic types of other embodiments of the explanatory capture probe 202 and the explanatory detectable probes 204a, 204b, 204c are shown in Figure 2A. The capture probe 102 comprises (1) a first segment containing a first polynucleotide having a first sequence, and (2) a second segment conjugated to the first segment, wherein the second segment contains a plurality of second polynucleotides 210a, 210b, 210c, each containing a second sequence. Multiple detectable probes 204a, 204b, and 204c are also present, each of which contains a third polynucleotide 216a, 216b, and 216c. The third polynucleotide is covalently bonded at one end to the first polymer containing the chromophore 214. In embodiments, the third polynucleotide has a third sequence that is at least 90% complementary to the second sequence.
[0092] Accordingly, compositions are described herein, comprising (1) a capture probe comprising a second segment, which includes (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides each comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a third polynucleotide having a first and a second end, the first end being covalently bonded to a first polymer comprising a chromophore, and the third polynucleotide having a third sequence having at least 90% complementarity to the second sequence. In some embodiments, the third polynucleotide has a length in the range of 10 to 40 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 10 to 30 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 15 to 25 nucleotides.
[0093] In some embodiments, the second sequence has at least 92% complementarity with the third sequence. In some embodiments, the second sequence has at least 95% complementarity with the third sequence. In some embodiments, the second sequence has at least 96% complementarity with the third sequence. In some embodiments, the second sequence has at least 97% complementarity with the third sequence. In some embodiments, the second sequence has at least 98% complementarity with the third sequence. In some embodiments, the second sequence has at least 99% complementarity with the third sequence. In some embodiments, the triple-stranded structure is formed by two detectable probe polynucleotides and a capture probe polynucleotide. As shown in Figure 2A, in some embodiments, each of the first polymers contains multiple chromophores. In some embodiments, a second type of detectable probe is also present. In some such embodiments, the detectable probe contains a third polynucleotide bound to the first polymer and / or the second polymer.
[0094] In some embodiments, at least a portion of the detectable probes have the structures (I), (II), (IIa), (IIb) described above, or a combination thereof. In some embodiments, at least one of the detectable probes has the structure (I) described above. In some embodiments, at least one of the detectable probes has the structure (II) described above. In some embodiments, at least one of the detectable probes has the structure (IIa) described above. In some embodiments, at least one of the detectable probes has the structure (IIb) described above. In some embodiments, each detectable probe has one of the structures described above (I), (II), (IIa), (IIb), or a combination thereof. In some embodiments, each detectable probe has one of the structures described above (I) (as illustrated in Figure 2A). In other embodiments, each detectable probe has one of the structures described above (II). In some embodiments, each detectable probe has one of the structures described above (IIa). In some embodiments, each detectable probe has one of the structures described above (IIb).
[0095] As also shown in Figure 2A, the fourth polynucleotide 220 was covalently bonded to the targeting moiety 222. In various embodiments, the fourth polynucleotide has a fourth sequence that is at least 90% complementary to the first sequence. In some embodiments, the fourth sequence is at least 92% complementary to the first sequence. In some embodiments, the fourth sequence is at least 95% complementary to the first sequence. In some embodiments, the fourth sequence is at least 96% complementary to the first sequence. In some embodiments, the fourth sequence is at least 97% complementary to the first sequence. In some embodiments, the fourth sequence is at least 98% complementary to the first sequence. In some embodiments, the fourth sequence is at least 99% complementary to the first sequence. In other embodiments, the targeting moiety is covalently bonded to the capture probe. Schematic types of other embodiments of the explanatory capture probe 202 and the explanatory detectable probes 204, 206a, 206b are shown in Figure 2B. The capture probe 102 comprises (1) a first segment containing a first polynucleotide having a first sequence, and (2) a second segment conjugated to the first segment, wherein the second segment contains a plurality of second polynucleotides 210a, 210b, 210c, each containing a second sequence.
[0096] Multiple detectable probes 204, 206a, and 206b are also present, each of which contains a third polynucleotide 216a, 216b, and 216c. The third polynucleotide is covalently bonded to one end of a first polymer containing an acceptor chromophore 214, and to the other end of a second polymer containing a donor chromophore 218. In other words, each of the multiple detectable probes contains a third polynucleotide having a first end and a second end, the first end covalently bonded to the first polymer containing the acceptor chromophore, and the second end covalently bonded to the second polymer containing the donor chromophore. In embodiments, the third polynucleotide has a third sequence having at least 90% complementarity to the second sequence. Accordingly, the following compositions are described herein: (1) a capture probe comprising a second segment comprising (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides each comprising a second sequence, and (2) a plurality of detectable probes, each of which comprises a plurality of detectable probes comprising a third polynucleotide having a first end and a second end, the first end being covalently bonded to a first polymer comprising an acceptor chromophore, the second end being covalently bonded to a second polymer comprising a donor chromophore, and the third polynucleotide having a third sequence having at least 90% complementarity to the second sequence.
[0097] In some embodiments, the second sequence has at least 92% complementarity with the third sequence. In some embodiments, the second sequence has at least 95% complementarity with the third sequence. In some embodiments, the second sequence has at least 96% complementarity with the third sequence. In some embodiments, the second sequence has at least 97% complementarity with the third sequence. In some embodiments, the second sequence has at least 98% complementarity with the third sequence. In some embodiments, the second sequence has at least 99% complementarity with the third sequence. In some embodiments, the triple-stranded structure is formed by two detectable probe polynucleotides and a capture probe polynucleotide.
[0098] As shown in Figure 2B, in some embodiments, each of the first polymers contains multiple chromophores. Similarly, in some embodiments, each of the second polymers contains multiple chromophores. In some embodiments, a second type of detectable probe 204 is also present. In some such embodiments, the detectable probe 204 contains a third polynucleotide bound to the first or second polymer. In some embodiments, the third polynucleotide has a length in the range of 10 to 40 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 10 to 30 nucleotides. In some embodiments, the third polynucleotide has a length in the range of 15 to 25 nucleotides. In some embodiments, at least a portion of the detectable probes have the structures (I), (II), (IIa), (IIb) described above, or a combination thereof. In some embodiments, at least one of the detectable probes has the structure (I) described above. In some embodiments, at least one of the detectable probes has the structure (II) described above. In some embodiments, at least one of the detectable probes has the structure (IIa) described above. In some embodiments, at least one of the detectable probes has the structure (IIb) described above.
[0099] In some embodiments, each detectable probe has one of the structures described above (I), (II), (IIa), (IIb), or a combination thereof. In some embodiments, each detectable probe has one of the structures described above (I). In some embodiments, each detectable probe has one of the structures described above (II). In some embodiments, each detectable probe has one of the structures described above (IIa). In some embodiments, each detectable probe has one of the structures described above (IIb). As also shown in Figure 2B, the fourth polynucleotide 220 was covalently bonded to the targeting moiety 222. In various embodiments, the fourth polynucleotide has a fourth sequence that is at least 90% complementary to the first sequence. In some embodiments, the fourth sequence is at least 92% complementary to the first sequence. In some embodiments, the fourth sequence is at least 95% complementary to the first sequence. In some embodiments, the fourth sequence is at least 96% complementary to the first sequence. In some embodiments, the fourth sequence is at least 97% complementary to the first sequence. In some embodiments, the fourth sequence is at least 98% complementary to the first sequence. In some embodiments, the fourth sequence is at least 99% complementary to the first sequence. In other embodiments, the targeting moiety is covalently bonded to the capture probe.
[0100] Another embodiment is illustrated in Figure 2C. The capture probe 102 includes (1) a first segment comprising a first polynucleotide having a first sequence, and (2) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides 210 each comprising a second sequence. Multiple branched linkers 226 and multiple detectable probes 204 are also present. Each of the multiple detectable probes contains a third polynucleotide 216 (having a third sequence), and each of the multiple branched linkers contains a fourth polynucleotide 228 (having a fourth sequence) and a fifth polynucleotide 224 (having a fifth sequence). The third polynucleotide is covalently bonded at one end to the first polymer containing the chromophore 214.
[0101] In some embodiments, the second sequence has at least 90% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 92% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 95% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 96% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 97% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 98% complementarity with the fourth sequence. In some embodiments, the second sequence has at least 99% complementarity with the fourth sequence. In some embodiments, the third sequence has at least 90% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 92% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 95% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 96% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 97% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 98% complementarity with the fifth sequence. In some embodiments, the third sequence has at least 99% complementarity with the fifth sequence.
[0102] In some embodiments, the second, third, fourth, and / or fifth polynucleotides have lengths ranging from 10 to 40 nucleotides. In some embodiments, the second, third, fourth, and / or fifth polynucleotides have lengths ranging from 10 to 30 nucleotides. In some embodiments, the second, third, fourth, and / or fifth polynucleotides have lengths ranging from 15 to 25 nucleotides. In some embodiments, the triple-stranded structure is formed by two detectable probe polynucleotides and a capture probe polynucleotide. In some embodiments, each of the first polymers contains a plurality of chromophores. In some embodiments, at least a portion of the detectable probes have structure (I). In some embodiments, at least one of the detectable probes has structure (I) as described above. In some embodiments, each of the detectable probes has structure (I) as described above.
[0103] In some embodiments, the sixth polynucleotide 220 is covalently bonded to the targeting moiety 222. In various embodiments, the sixth polynucleotide has a sixth sequence that is at least 90% complementary to the first sequence. In some embodiments, the sixth sequence is at least 92% complementary to the first sequence. In some embodiments, the sixth sequence is at least 95% complementary to the first sequence. In some embodiments, the sixth sequence is at least 96% complementary to the first sequence. In some embodiments, the sixth sequence is at least 97% complementary to the first sequence. In some embodiments, the sixth sequence is at least 98% complementary to the first sequence. In some embodiments, the sixth sequence is at least 99% complementary to the first sequence. In other embodiments, the targeting moiety is covalently bonded to the capture probe.
[0104] Accordingly, the following compositions are described herein: (1) a capture probe comprising a second segment comprising (i) a first segment comprising a first polynucleotide having a first sequence, and (ii) a second segment conjugated to the first segment, wherein the second segment comprises a plurality of second polynucleotides each comprising a second sequence; and (2) a plurality of detectable probes, each of which comprises a plurality of detectable probes comprising a third polynucleotide having a first end and a second end, the first end being covalently bonded to a first polymer comprising a chromophore, and the third polynucleotide having a third sequence; and (3) a plurality of branched linkers comprising a polymer backbone bonded to a fourth polynucleotide, and a plurality of fifth polynucleotides, wherein the fourth polynucleotide has a fourth sequence having at least 90% complementarity with the second sequence, and each of the fifth polynucleotides comprises a fifth sequence having at least 90% complementarity with the third sequence.
[0105] Kits containing the capture probes, detectable probes, or both described herein are also described herein. In some such embodiments, the kits of the Disclosure further include instructions for use of the compounds, compositions, or detectable probes for identifying target nucleotide sequences. A method for identifying the presence of a target analyte is further described, comprising the steps of generating a mixture by contacting a sample with a composition described herein under assay conditions, and imaging the mixture under detection conditions. In some embodiments, the step of imaging the mixture includes the steps of exciting a donor fluorophore at a first wavelength and detecting the emission of an acceptor fluorophore at a second wavelength. [Examples]
[0106] General method Mass spectroscopy was performed using a Waters / Micromass Quattro micro-MS / MS system (MS-only mode) with MassLynx 4.1 acquisition software. The mobile phase used for LC / MS of the dye was 100 mM 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 8.6 mM triethylamine (TEA), pH 8. Phosphoramidite and precursor molecules were also analyzed using a Waters Acquity UHPLC system with a 2.1 mm × 50 mm Acquity BEH-C18 column maintained at 45°C, employing an acetonitrile / water mobile phase gradient. Molecular masses of monomer intermediates were obtained using tropylium cation infusion enhanced ionization on a Waters / Micromass Quattro micro-MS / MS system (MS-only mode). Excitation and emission profile experiments were recorded using a Cary Eclipse spectrophotometer.
[0107] All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless otherwise specified. Commercial DNA synthesis reagents were purchased from Glen Research (Sterling, VA). Anhydrous pyridine, toluene, dichloromethane, diisopropylethylamine, triethylamine, acetic acid, pyridine, and THF were purchased from Aldrich. All other chemicals were purchased from Aldrich or TCI and used without further purification.
[0108] (Example 1) Synthesis of dyes containing ethylene glycol spacers Compounds containing ethylene oxide linker were prepared as follows. Oligofluoroside constructs (e.g., compounds of structures (I), (II), or (III)) were synthesized using a 1 μmol scale Applied Biosystems 394 DNA / RNA synthesizer and possessed either a 3'-phosphate group, a 3'-S2-(CH2)6-OH group, or any other group described herein. Synthesis was carried out directly on CPG beads or polystyrene solid supports using standard phosphoramidite chemistry. Oligofluorosides were synthesized in the 3' to 5' direction using standard solid-phase DNA methods and coupling with standard β-cyanoethyl phosphoramidite chemistry. Fluoroside and nucleoside phosphoramidites, spacers (e.g., hexaethyloxy-glycol phosphoramidite, triethyloxy-glycol phosphoramidite, polyethylene glycol phosphoramidite), and linkers (e.g., 5'-amino-modifier phosphoramidite, and thiol-modifier S2 phosphoramidite) were dissolved in acetonitrile to prepare 0.1 M solutions, which were then added in sequence using the following synthetic cycle: 1) removal of the 5'-dimethoxytrityl protecting group with dichloroacetic acid in dichloromethane, 2) coupling of the next phosphoramidite with an activating reagent in acetonitrile, 3) formation of a stable P(v) by oxidation of P(III) with iodine / pyridine / water, and 4) coupling of any unreacted 5'-hydroxyl group with acetic anhydride / 1-methylimidazole / acetonitrile. The synthetic cycle was repeated until a full-length oligofluoroside construct was assembled. At the end of the chain assembly, monomethoxytrityl (MMT) or dimethoxytrityl (DMT) groups were removed with dichloroacetic acid in dichloromethane.
[0109] The compound was supplied in 0.2 μmol scale to a controlled-pore glass (GCP) support in a labeled Eppendorf tube. 400 μL of 20-30% NH4OH was added and gently mixed. The open tube was placed at 55°C for approximately 5 minutes, or until excess gas was released, then sealed and incubated for 2 hours (+ / - 15 minutes). The tube was removed from the heat block and allowed to reach room temperature, then centrifuged at 13,400 RPM for 30 seconds to solidify the supernatant and solids. The supernatant was carefully removed and placed in the labeled tube, and the support was washed with 150 μL of acetonitrile. After adding the washing solution to the tube, it was placed in a CentriVap instrument at 40°C until dry. The products were characterized by ESI-MS, UV absorbance, and fluorescence spectroscopy.
[0110] (Example 2) Spectral analysis of compounds The dried compound was reconstituted with 150 μL of 0.1 M Na2CO3 buffer to prepare a stock solution of approximately 1 mM. The concentrated stock solution was diluted 50x with 0.1 × PBS and analyzed using a NanoDrop UV spectrometer to obtain absorbance readings. The absorbance readings were used to determine the extinction coefficient (75,000 M in each FAM unit). -1 cm -1 The actual concentration of the storage solution was determined using this method in conjunction with Baer's Law. Based on the calculated storage solution concentration, approximately 4 mL of a 5 μM solution was prepared in 0.1 M Na2CO3 (pH 9), and analyzed in a 1 × 1 cm quartz cuvette using a Cary 60 UV spectrometer with a spectral range of 300 nm to 700 nm to measure the overall absorbance for the group. From these 5 μM solutions, a second dilution was prepared at 50 nM or 25 nM (also in 0.1 M Na2CO3, pH 9) for spectroscopic analysis using a Cary Eclipse Fluorimeter. Excitation was set to 494 nm, and emission spectra were collected in the 499–700 nm range.
[0111] (Example 3) Signal amplification by concatenation The biotinylated target probe (5'-B-heg-ATGCACAGTCGG-dT-3') (SEQ ID NO: 1), conjugated to neutraavidin beads mixed with the first probe (5'-CGA CGC TTA CAG-heg-F-(hegheg-F)3-heg-CCG ACT GTG CA-dT-3') (SEQ ID NO: 1), was analyzed individually and using flow cytometry. (1) The first probe (5'-CGA CGC TTA CAG-heg-F-(heghegheg-F)3-heg-CCG ACT GTG CA-dT-3') (SEQ ID NO: 2) was also analyzed using flow cytometry.
[0112] The stock was heated to 94°C for 10 minutes using a thermal cycler, then cooled and maintained at 37°C until use. 5 nanograms (ng) of capture probe per sample were bound to 30 µl of neutraavidin-coated beads by incubation at room temperature in the dark for 30 minutes. The beads were washed with hybridization buffer (10 mM Tris-HCl, 4 mM mgCl, 15 mM KCl, pH 8.2) and centrifuged at 400 × g for 5 minutes. The supernatant was removed and the samples were resuspended in cell staining buffer. For conditions 1 and 2, 1 µl of 100 µM of the first probe was added, the samples were incubated at room temperature for 10 minutes, and then washed with hybridization buffer. The samples were centrifuged at 400 × g for 5 minutes, the supernatant was removed, and the samples were resuspended in cell staining buffer or treated with the second probe. For condition 2, 1 µl of a 100 µM second probe was added, the sample was incubated at room temperature for 10 minutes, and then washed with hybridization buffer. The sample was centrifuged at 400 × g for 5 minutes, and the supernatant was removed. The sample was resuspended in cell staining buffer and analyzed using an SA3800 flow cytometer. The results are shown in Figure 4.
[0113] (Example 4) Branch amplification 5 ng of biotinylated target probe (5'-biotin-heg-TTT CTT TGA GGT TTA GGA TTC-dT-3') (SEQ ID NO: 4) conjugated to neutraavidin beads, 200 pmol of target amplified product (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5') (SEQ ID NO: 5), and (1) 5'-CCA ACC GGA ATC CCA AG XF-dT-3' (SEQ ID NO: 6), 5'-CCA ACC GGA ATC CCA AG-heg-F (heghegheg-F)3-heg-dT-3' (SEQ ID NO: 7); (2) 5'-CCA ACC GGA ATC CCA AG XF-dT-3' (SEQ ID NO: 6), 5'-CCA ACC GGA ATC Mix with multiple detection probes selected from CCA AG-heg-F(heghegheg-F)4-heg-dT-3' (SEQ ID NO: 8) and (3)5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)9-heg-dT-3' (SEQ ID NO: 9).
[0114] The probe stock was heated to 94°C for 10 minutes using a thermal cycler, then cooled and maintained at 37°C until use. 5 ng of capture probe per sample was conjugated to neutraavidin beads by incubation at room temperature in the dark for 30 minutes. The beads were washed with hybridization buffer and centrifuged at 400 × g for 5 minutes, with the supernatant removed. 200 pmol of target amplifier was added, and the sample was incubated at 37°C for 10 minutes, followed by washing with hybridization buffer as described above. 400 pmol of detection probe was added, and the sample was incubated at 37°C for 10 minutes. The sample was washed with hybridization buffer as described above and resuspended in cell staining buffer for analysis using an SA3800 flow cytometer.
[0115] (Example 5) Branch amplification The capture probe was mixed with (1) 200 pmol of the target amplification (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5') (SEQ ID NO: 5), and (2) multiple detectable probes and 200 pmol of the target amplification (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5') (SEQ ID NO: 5), and 400 pmol of multiple detection probes (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)3-heg-dT-3') (SEQ ID NO: 7). The results are shown in Figure 5. After hybridization with the 4× amplified product (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)3-heg-dT-3';A03) (SEQ ID NO: 7), there was an approximately 9-fold increase in fluorescence.
[0116] (Example 6) Branch amplification The sample is captured by a capture probe (A01); capture probe + target (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5') (SEQ ID NO: 5)-(A02); capture probe + target (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5') (SEQ ID NO: 5) + 5 × amplified product (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)4-heg-dT-3') (SEQ ID NO: 8)-(A03); capture probe + target (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5')(SEQ ID NO: 5) + 10 × Amplifier (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)9-heg-dT-3')(SEQ ID NO: 9)-(A04); Target (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5')(SEQ ID NO: 5) + 5 × Amplifier (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)4-heg-dT-3')(SEQ ID NO: 8)-(A05); and Target (3'-dT-AAA GAA ACT CCA AAT CCT AAG-GGT TGG CCT TAG GGT TC AGA-GGT TGG CCT TAG GGT TC AGA-heg-F-5')(SEQ ID NO: 5) + 10× amplified product (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)9-heg-dT-3')(SEQ ID NO: 9)-(A06) were incubated with these products at 37°C for 10 minutes. The results are shown in Figure 6.After hybridization with the 5× amplified product (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)4-heg-dT-3') (SEQ ID NO: 8), there was an approximately 11-fold increase in fluorescence, and after hybridization with the 10× amplified product (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)9-heg-dT-3') (SEQ ID NO: 9), there was an approximately 16-fold increase in fluorescence.
[0117] (Example 7) Concatemer amplification The biotinylated target probe (5'-B-heg-ATGCACAGTCGG-dT-3') (SEQ ID NO: 1), bound to (3'-d-TACGTGTCAGCC-heg-F(heghegheg-F)3-heg-GACATTCGCAGC-5') (SEQ ID NO: 10), is mixed with a second probe (5'-CTGTAAGCGTCG-heg-F(heghegheg-F)4-heg-CGACGCTTACAG-dT-3') (SEQ ID NO: 11), and concatemerized in a zigzag manner (as shown in Figure 7). The resulting structure is then examined.
[0118] (Example 8) Stepwise linear probe hybridization in solution The first probe (3'-dT-AAA GAA ACT CCA ATC CTA AG-heg-F(heghegheg-F)-heg-GGT TGG CCT TAG GGT TC-5') (SEQ ID NO: 12) was mixed with the second probe (5'-CCA ACC GGA ATC CCA AG-heg-F(heghegheg-F)-heg-CTT TGA GGT TTA GGA T-dT-3') (SEQ ID NO: 13) under various conditions for hybridization (200 μM stock of each probe was heated at 94 °C for 5 minutes, and then mixed 1:1 for a final concentration of 100 μM each). The results are shown in Figure 8. Individual probes were found at approximately 7.6 m, hybridized probes started at approximately 6.8 m (estimated single hybridization), and longer multimers were observed at 4.2–5.5 m, which were not completely dissolved. Incubation at 37°C resulted in longer chains.
[0119] Furthermore, as shown in Figure 8B, hybridization of the first probe to the second probe resulted in an approximately 1.6-fold increase in fluorescence. However, further incubation with the first probe, followed by the second probe, did not increase fluorescence. Incubation with the pre-hybridization material containing the polymer from solution analysis did not show a further increase in fluorescence. Further embodiments can be provided by combining the various embodiments described above. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referenced in this application and / or listed in the application datasheet, including U.S. Provisional Patent Application No. 63 / 118,544 filed November 25, 2020, are incorporated herein by reference in their entirety. The aspects of the embodiments may be modified if it is necessary to provide further embodiments using various patent, application, and publication concepts. These and other modifications can be made to embodiments in accordance with the descriptions detailed above. In general, the terms used in the following claims should not be interpreted as limiting the claims to the specific embodiments disclosed herein and in the claims, but rather as encompassing all possible embodiments, along with the broader scope of equivalents to which such claims are granted. Thus, the claims are not limited by this disclosure.
Claims
1. A compound having the following structure (II): or a stereoisomer, salt, or tautomer thereof: 【Chemistry 1】 (II) (In the formula, M, independently in each occurrence, is a chromophore; L 1a is, independently in each occurrence, a heteroarylene linker; L 2 and L 8 are independently an optional linker, L 1b , L 3 , L 5 , L 6 and L 7 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently in each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 9 is a linker comprising a polynucleotide, R 1 and R 2 are each independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, or -OP(=R a ) (R b ) R c and R 3 is independently at each occurrence H, alkyl, or alkoxy; R 4 is independently in each occurrence OH, SH, O - , S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O - , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counterion, L' is, independently in each occurrence, a linker that includes a covalent bond to a solid support, a linker that includes a covalent bond to a solid support moiety, or a linker that includes a covalent bond to a nucleoside; m is independently in each occurrence an integer that is equal to or greater than zero; n is an integer of 1 or more, q and w are independently 0 or 1 in each occurrence, provided that at least one occurrence of either q or w is 1;
2. A) M is, independently in each occurrence, the same or different donor chromophore; B) M is, independently in each occurrence, the same or different acceptor chromophore; C) M is, independently in each occurrence, the same or a different fluorophore; D) M is, independently in each occurrence, the same or a different donor fluorophore; E) M is, independently in each occurrence, the same or different acceptor fluorophore; F) M is, independently for each occurrence, a dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,10-ethynylanthracene, or ter-naphthyl moiety; G) M is, independently in each occurrence, pyrene, perylene, perylene monoimide, 5-FAM, or 6-FAM, or a derivative thereof; H) M is independently in each occurrence the following structure: 【Chemistry 2】 or I) M has, independently in each occurrence, one of the following structures: 【Chemistry 3】 【change】 【change】 【change】 The compound of claim 1 having one of the following:
3. A compound having the following structure (III): or a stereoisomer, salt, or tautomer thereof: 【Chemistry 4】 (III) (In the formula, M is, independently at each occurrence, the same or a different fluorophore, a molecule capable of absorbing light of a particular frequency and emitting light of a different frequency; L 1a is, independently in each occurrence, a heteroarylene linker; L 2 and L 8 is non-existent, L 1b , L 3 , L 5 , L 6 and L 7 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently in each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 10 is a linker comprising a polynucleotide, R 1 is H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a ) (R b ) R c or a moiety comprising a polynucleotide, R2 comprises a polynucleotide; R 3 is independently at each occurrence H, alkyl, or alkoxy; R 4 is independently in each occurrence OH, SH, O - , S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O - , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counterion, L' has the following structure: 【change】 (In the formula, m″ and n″ are independently integers from 1 to 10; R e is H, an electron pair or a counter ion; L″ is R e or a direct bond or linkage to a solid support or a nucleoside; m is independently in each occurrence an integer that is equal to or greater than zero; n is an integer of 2 or more, q and w are independently 0 or 1 in each occurrence, provided that at least one occurrence of either q or w is 1;
4. A) R 1 comprises a targeting moiety attached to the polynucleotide; and / or B) R 2 The compound of claim 3 , wherein the targeting moiety is an antibody, the targeting moiety being linked to a polynucleotide.
5. A) M is, independently in each occurrence, the same or a different donor fluorophore; B) M is the same donor fluorophore in each occurrence; C) M is, independently in each occurrence, the same or a different acceptor fluorophore, preferably M is the same acceptor fluorophore in each occurrence; D) M is, independently for each occurrence, a dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,10-ethynylanthracene, or ter-naphthyl moiety; E) M is, independently in each occurrence, pyrene, perylene, perylene monoimide, 5-FAM, or 6-FAM, or a derivative thereof; F) M independently in each occurrence has the following structure: 【Chemistry 5】 or G) M has, independently in each occurrence, the structure: 【Chemistry 6】 【change】 【change】 【change】 5. The compound according to claim 3, wherein
6. A composition comprising a compound according to any one of claims 1 to 5, and a compound having the following structure (I) or a stereoisomer, salt or tautomer thereof: 【Chemistry 7】 (I) (In the formula, M is, independently at each occurrence, the same or a different fluorophore, a molecule capable of absorbing light of a particular frequency and emitting light of a different frequency; L 1a is, independently in each occurrence, a heteroarylene linker; L 2 and L 8 are independently an optional linker, L 1b , L 3 , L 5 , L 6 and L 7 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently in each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; R 1 and R 2 is R 1 and R 2 are each independently selected from H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a ) (R b ) R c or a moiety comprising a polynucleotide, R 3 is independently at each occurrence H, alkyl, or alkoxy; R 4 is independently in each occurrence OH, SH, O - , S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O - , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counterion, L' is, independently in each occurrence, a linker that includes a covalent bond to a solid support, a linker that includes a covalent bond to a solid support moiety, or a linker that includes a covalent bond to a nucleoside; m is independently in each occurrence an integer that is equal to or greater than zero; n is an integer of 1 or more, q and w are independently 0 or 1 in each occurrence, provided that at least one occurrence of either q or w is 1;
7. R 1 Or R 2 The polynucleotide has a first sequence, 10 has a second sequence, the first sequence having at least 90% complementarity to at least a first portion of the second sequence, preferably: A) the first sequence has at least 92% complementarity to a portion of the first sequence; B) the first sequence has at least 95% complementarity to a portion of the first sequence; C) the first sequence has at least 97% complementarity to a portion of the first sequence; D) the first sequence has at least 98% complementarity to a portion of the first sequence; E) The composition of claim 6, wherein the first sequence has at least 99% complementarity to a portion of the first sequence.
8. A) the first sequence, a portion of the second sequence, or both, have a length in the range of 10 nucleotides to 40 nucleotides; and / or B) the first sequence, a portion of the second sequence, or both, have a length in the range of 10 nucleotides to 30 nucleotides; and / or C) the first sequence, a portion of the second sequence, or both, have a length in the range of 15 to 25 nucleotides; and / or D) the second sequence comprises a second portion that is identical to the first portion; and / or E) The composition of claim 6 or 7, further comprising a targeting moiety attached to a linked polynucleotide having a third sequence having at least 90% complementarity to at least a third portion of the second sequence, wherein the targeting moiety is an antibody.
9. A compound or composition according to any one of claims 1 to 8, wherein each occurrence of q is 0.
10. A compound or composition according to any one of claims 1 to 9, wherein at least one occurrence of q is 1.
11. A compound or composition according to any one of claims 1 to 10, wherein each occurrence of w is 0.
12. A compound or composition according to any one of claims 1 to 11, wherein at least one occurrence of w is 1.
13. L 4 at least one occurrence of is heteroalkylene, or L 4 13. The compound or composition of any one of claims 1 to 12, wherein each occurrence of is heteroalkylene, preferably the heteroalkylene comprises an alkylene oxide, more preferably the heteroalkylene comprises an ethylene oxide.
14. L 4 14. The compound or composition of claim 13, wherein: 【Chemistry 8】 (In the formula, z is an integer from 1 to 100, preferably z is an integer from 3 to 6 or an integer from 22 to 26; and * indicates a bond to the adjacent phosphorus atom)
15. A) L 1a is independently in each occurrence an optionally substituted 5- to 7-membered heteroarylene linker; or L 1a has one of the following structures: 【Chemistry 9】 B) L 3 is an alkylene linker, or L 3 each occurrence of is an alkylene linker; C) L 5 And / or L 6 is alkylene, or L 5 And / or L 6 each occurrence of is alkylene; D) L 1b independently in each occurrence, contains an amide functionality or a triazolyl functionality; E) L 7 At least one occurrence of is an optionally substituted heteroalkylene linker, or L 7 each occurrence of is independently an optionally substituted heteroalkylene linker; F) L 7 contains an amide or triazolyl functional group; G) L 7 Each occurrence of 【Chemistry 10】 having one of the following: H) n is an integer from 1 to 100, or n is an integer from 1 to 10; or I) The compound or composition according to any one of claims 1 to 14, wherein m is an integer from 3 to 6, or m is 3.
16. A kit comprising a compound or composition according to any one of claims 1 to 15 and instructions for use.
17. 1. A method for identifying the presence of a target analyte, comprising: generating a mixture by contacting the sample with a composition according to any one of claims 6 to 16 under assay conditions; and Imaging the mixture under detection conditions and preferably, the step of imaging the mixture comprises: exciting a donor fluorophore at a first wavelength; and Detecting the emission of the acceptor fluorophore at a second wavelength. A method comprising:
